Subcision acne scar treatment in Singapore is a minimally invasive procedure used to treat rolling, depressed and tethered acne scars caused by fibrotic bands beneath the skin.
These structural scars form when acne inflammation damages collagen and creates scar tissue that anchors the skin downward, resulting in visible indentations and uneven skin texture.
Subcision works by releasing these fibrotic attachments while stimulating collagen regeneration beneath the scar. This improves scar depth, enhances dermal support and promotes gradual skin remodelling.
For moderate to severe acne scars, subcision is often combined with collagen-stimulating treatments such as Rejuran Scar and polynucleotide-based regenerative therapy to support long-term dermal repair and scar improvement.
A personalised assessment helps determine whether acne scars are tethered and suitable for subcision treatment.
Subcision acne scar treatment is a minimally invasive surgical procedure used to treat rolling, depressed and tethered acne scars by releasing fibrotic bands beneath the skin. These fibrous strands form after severe acne inflammation damages collagen and creates scar tissue that anchors the skin downward, resulting in visible indentations and uneven skin texture.
Unlike surface treatments that focus only on skin resurfacing, subcision targets the structural cause of atrophic acne scars at the dermal level. By correcting the underlying tethering, it allows long-term scar improvement rather than temporary surface smoothing.
Depressed acne scars develop when inflammatory acne destroys collagen in the deeper layers of the skin. During healing, abnormal scar tissue forms and attaches the skin to underlying structures.
This creates:
The fibrotic bands act like internal anchors, pulling the skin downward and preventing it from returning to a smooth surface.
Subcision acne scar treatment involves inserting a specialised needle or blunt cannula beneath the scar. The instrument is carefully moved in a controlled motion to break the fibrotic strands tethering the scar.
Once released:
This mechanical correction addresses the root cause of rolling and tethered acne scars.
In addition to releasing scar tethering, subcision stimulates the bodyโs natural wound healing response. The controlled micro-injury triggers:
Over several weeks, newly formed collagen fills in the treated area, further improving acne scar depth and skin texture.
This dual mechanism โ mechanical release plus collagen stimulation โ is why subcision acne scar treatment in Singapore is considered a foundational treatment for structurally depressed scars.
Laser treatments primarily improve skin texture and stimulate collagen from the surface. However, if fibrotic tethering remains intact, the scar may continue to appear depressed despite multiple laser sessions.
Subcision works at a deeper structural level by correcting the anchoring beneath the scar. For many patients with rolling or tethered acne scars, subcision is necessary before collagen-stimulating or resurfacing treatments can achieve optimal results.
Subcision acne scar treatment works by correcting the structural tethering beneath depressed scars while simultaneously stimulating collagen regeneration. This dual-action mechanism allows both immediate lifting of scars and gradual long-term skin remodelling.
Depressed and rolling acne scars often form when fibrotic scar bands anchor the skin to deeper tissue layers. These fibrous attachments prevent the skin from returning to a smooth surface, resulting in visible depressions.
During subcision, a specialised needle or blunt cannula is inserted beneath the scar and moved in a controlled motion to break these fibrotic strands. As the tethering is released:
This mechanical release directly addresses the root structural cause of tethered acne scars.
The subcision process creates a controlled micro-injury beneath the scar. This stimulates the bodyโs natural wound-healing cascade, which is essential for long-term scar improvement.
Following subcision:
This biological response helps rebuild the dermal support beneath the scar.
Over the following weeks, newly formed collagen gradually fills the space beneath the released scar. This leads to:
Unlike temporary fillers, this collagen regeneration provides progressive and more sustained improvement in acne scar appearance.
Subcision produces two phases of improvement:
Immediate improvement
Gradual improvement
Multiple sessions may be required for deeper or long-standing tethered scars to achieve optimal improvement.
If fibrotic tethering is not released, collagen-stimulating or resurfacing treatments alone may not fully improve depressed scars. The anchoring beneath the scar continues to pull the skin downward, limiting results.
Subcision addresses this structural problem first, allowing subsequent treatments such as collagen-stimulating injectables or laser therapies to work more effectively. This is why subcision acne scar treatment in Singapore is often considered a foundational step in comprehensive acne scar management.
Subcision acne scar treatment is most effective for scars caused by dermal tethering. Identifying the correct scar type is important, as not all acne scars respond equally to subcision. The procedure works best when fibrotic bands beneath the skin are responsible for pulling the scar downward.
Rolling acne scars are the most responsive to subcision treatment. These scars appear as broad, shallow depressions with smooth sloping edges and are commonly caused by fibrotic tethering beneath the skin.
Subcision directly releases these tethering bands, allowing the skin to lift. Most patients with rolling acne scars experience significant improvement after subcision, especially when collagen regeneration occurs during the healing process.
Boxcar scars have more defined edges and a wider base compared to rolling scars. When boxcar scars are deeply anchored by fibrotic attachments, subcision can help release the tethering and reduce the depth of the scar.
However, shallow boxcar scars without significant tethering may respond better to resurfacing or collagen-stimulating treatments rather than subcision alone.
Many patients have a combination of rolling, boxcar and other atrophic scars. In these cases, subcision is selectively performed on scars that demonstrate dermal tethering, while other treatments may be used to address different scar components.
This targeted approach allows comprehensive improvement in overall skin texture and scar appearance.
Icepick scars are narrow, deep and vertically oriented scars that extend into the dermis. Because these scars are usually not caused by tethering, subcision alone is less effective.
Additional targeted treatments are often required for optimal improvement of icepick scars.
Older and deeper acne scars tend to have stronger fibrotic attachments beneath the skin. These scars often require multiple subcision sessions to fully release tethering and stimulate sufficient collagen remodelling.
Despite being more challenging, meaningful improvement can still be achieved with staged treatment.
A clinical assessment is necessary to determine whether acne scars are tethered and suitable for subcision. Treating the correct scar type ensures:
Subcision acne scar treatment in Singapore is most effective when tailored to the patientโs specific scar pattern and degree of dermal tethering.
While subcision releases fibrotic tethering and lifts depressed acne scars, rebuilding the dermal structure beneath the skin is important for sustained scar improvement. Collagen-stimulating treatments help restore skin thickness, improve dermal support and enhance long-term outcomes after subcision.
For many patients with moderate to severe acne scars, combination therapy provides more comprehensive and durable improvement compared to subcision alone.
After fibrotic tethering is released, a small space forms beneath the scar. Without adequate collagen regeneration, the skin may not maintain its lifted position over time.
Collagen-stimulating treatments support:
This strengthens and maintains the lifting achieved by subcision.
Subcision is commonly combined with Rejuran Scar, a polynucleotide-based injectable treatment used for acne scar repair. Polynucleotides (PN) help stimulate fibroblast activity, promote tissue regeneration and support collagen remodelling within the dermis.
Rejuran Scar works by:
More information about this treatment can be found here:
https://botoxsingapore.sg/rejuran-s-acne-scar-treatment-singapore/
When subcision is combined with Rejuran Scar and polynucleotide-based regenerative therapy:
This combination targets both the structural and biological causes of acne scars.
Subcision combined with Rejuran Scar may be recommended for:
Treatment is individualised based on scar severity, scar type and skin condition.
Subcision acne scar treatment in Singapore is often used as a foundational step in managing structurally depressed scars. When combined with Rejuran Scar and polynucleotide-based collagen stimulation, it helps achieve more complete dermal repair and longer-lasting improvement in acne scar appearance.
A personalised treatment approach allows targeted correction of tethering, collagen loss and dermal damage for optimal results.
The number of subcision sessions required depends on the severity of acne scars, the degree of dermal tethering, and the skinโs response to collagen regeneration. While some patients see improvement after a single treatment, deeper or long-standing scars often require multiple sessions for optimal results.
Subcision works progressively, with each session further releasing tethered scars and stimulating additional collagen remodelling.
The recommended number of sessions varies depending on scar depth and structural tethering.
A personalised assessment helps determine the appropriate treatment plan.
Deeper acne scars often have stronger fibrotic attachments beneath the skin. Releasing these tethered bands completely may require more than one session. In addition, collagen regeneration occurs gradually, and repeated stimulation helps improve dermal thickness and scar support over time.
Multiple sessions allow:
Subcision sessions are usually spaced several weeks apart to allow adequate healing and collagen remodelling.
During this interval:
Spacing treatments appropriately helps optimise scar improvement while minimising risk.
Combining subcision with collagen-stimulating treatments such as Rejuran Scar and polynucleotide-based regenerative therapy may enhance dermal repair and support collagen regeneration. In some cases, this may improve overall scar response and reduce the number of sessions required to achieve meaningful improvement.
Initial lifting from mechanical release may be seen shortly after treatment. However, most improvement develops gradually over several weeks as collagen remodelling occurs beneath the skin.
Full assessment of scar improvement is usually performed after sufficient healing and dermal regeneration have taken place.
Subcision acne scar treatment is a minimally invasive in-clinic procedure performed under local anaesthesia. The goal is to release fibrotic tethering beneath depressed acne scars while stimulating collagen regeneration for gradual skin remodelling.
The procedure is carefully performed to target structurally tethered scars while minimising trauma to surrounding tissue.
Before the procedure, the skin is cleansed and disinfected to maintain sterility. Local anaesthetic is administered to ensure comfort during treatment. Once the area is numbed, the doctor identifies tethered acne scars that require release.
Proper preparation helps minimise discomfort and ensures accurate targeting of scar tethering.
A specialised needle or blunt cannula is inserted beneath the scar through a small entry point in the skin. The instrument is gently moved in a controlled motion to break fibrotic strands anchoring the scar to deeper tissue.
During the procedure:
This controlled release allows the skin to elevate and improves scar contour.
The procedure typically takes 15 to 30 minutes depending on the number and severity of scars treated. More extensive or deeper scars may require slightly longer treatment time.
Subcision is usually performed as an outpatient procedure, and patients can return home shortly after treatment.
Because local anaesthesia is used, most patients experience minimal discomfort. Some pressure or movement may be felt beneath the skin as the fibrotic bands are released.
The procedure is generally well tolerated and does not require general anaesthesia.
Recovery after subcision acne scar treatment is generally well tolerated. Most side effects are temporary and part of the normal healing process that supports collagen regeneration and scar improvement. The degree of downtime varies depending on the extent of subcision performed and individual healing response.
After subcision treatment, it is normal to experience mild to moderate temporary effects as the skin heals and collagen remodelling begins.
Common effects include:
These effects are expected and usually improve progressively over time.
Bruising and swelling are typically most noticeable within the first few days after treatment and gradually improve over time.
Healing time varies depending on the depth of scars treated and individual skin response.
Subcision stimulates a controlled wound-healing response beneath the skin. During the healing phase:
Most visible improvement develops gradually over several weeks to months.
Most patients are able to resume normal daily activities shortly after subcision treatment. However, depending on the extent of bruising or swelling, some patients may prefer to allow a few days for recovery before social activities.
Light activities can usually be resumed quickly, while avoiding excessive pressure or trauma to treated areas during the early healing phase.
Recovery time and response to treatment may vary depending on:
Proper healing supports optimal scar improvement and long-term dermal remodelling.
Subcision acne scar treatment is a well-established and generally safe procedure when performed using proper technique and sterile precautions. Most side effects are temporary and related to the normal healing process following release of fibrotic tethering and collagen stimulation.
Understanding potential risks helps patients make informed decisions and ensures appropriate treatment planning.
Temporary effects after subcision are common and usually resolve as healing progresses.
These may include:
These effects are part of the normal healing response and typically improve over time.
Although uncommon, the following risks may occur:
These risks are minimised with proper technique, sterile conditions and appropriate aftercare.
Post-inflammatory pigmentation is less common with subcision compared to surface-based laser treatments because subcision works beneath the skin rather than causing superficial thermal injury. However, it may still occur in some individuals and usually improves gradually over time.
Safety during subcision is achieved through:
Proper technique reduces risk while optimising scar improvement.
Although complications are uncommon, medical review may be required if:
Early assessment helps ensure proper management and healing.
Subcision acne scar treatment is most suitable for individuals with depressed, rolling or tethered acne scars caused by fibrotic bands beneath the skin. Proper patient selection is important to ensure effective scar improvement and optimal treatment outcomes.
A clinical assessment is required to determine whether acne scars are structurally tethered and suitable for subcision.
Subcision may be recommended for patients who have:
Subcision works best when the underlying cause of the scar is fibrotic tethering rather than superficial skin damage.
Subcision may not be recommended in certain situations, including:
Treatment suitability should be assessed individually.
A proper scar assessment helps determine:
Targeted treatment planning improves scar response and overall skin texture.
Subcision acne scar treatment can be performed on most skin types, including Asian skin. Because the procedure works beneath the skin rather than causing surface thermal injury, the risk of post-inflammatory pigmentation is generally lower compared to some resurfacing treatments.
Every patientโs acne scar pattern is different. A personalised approach allows the doctor to identify tethered scars, determine appropriate treatment depth and decide whether combination therapy may provide better dermal repair and scar improvement.
Subcision acne scar treatment in Singapore is most effective when tailored to the individualโs scar type, skin condition and collagen response.
Does Subcision Permanently Remove Acne Scars
Subcision improves acne scars by releasing fibrotic tethering and stimulating collagen regeneration beneath the skin. While acne scars may not disappear completely, significant and long-lasting improvement in scar depth and skin texture is commonly achieved. Results continue to improve over time as collagen remodelling occurs.
Is Subcision Painful
Subcision is performed under local anaesthesia, and most patients experience minimal discomfort during the procedure. Some pressure or movement may be felt as the fibrotic bands are released, but the treatment is generally well tolerated.
How Long Does It Take To See Results After Subcision
Some improvement may be seen shortly after treatment due to mechanical release of tethered scars. However, most visible improvement develops gradually over several weeks to months as collagen regeneration and dermal remodelling occur beneath the skin.
How Many Subcision Sessions Are Usually Needed
The number of sessions depends on scar severity and depth of tethering. Mild scars may improve after one session, while deeper or long-standing scars often require multiple treatments spaced over time for optimal improvement.
Can Subcision Be Combined With Other Acne Scar Treatments
Yes. Subcision is commonly combined with collagen-stimulating treatments such as Rejuran Scar and polynucleotide-based regenerative therapy to enhance dermal repair and improve long-term scar outcomes. Combination therapy targets both structural tethering and collagen loss for more comprehensive scar improvement.
Is Subcision Safe For Asian Skin
Subcision can be safely performed on most skin types, including Asian skin. Because the treatment works beneath the skin rather than causing surface thermal injury, the risk of post-inflammatory pigmentation is generally lower compared to some resurfacing treatments.
What Is The Downtime After Subcision Acne Scar Treatment
Most patients experience temporary swelling, bruising and mild tenderness after treatment. Bruising usually improves within about 5 to 7 days. Normal activities can typically be resumed shortly after the procedure.
Can Acne Scars Return After Subcision
Once fibrotic tethering is released and collagen regeneration occurs, improvement is usually long-lasting. However, deeper scars may require more than one session, and ongoing collagen remodelling contributes to sustained scar improvement.
Who Is A Good Candidate For Subcision Acne Scar Treatment
Subcision is most suitable for patients with depressed, rolling or tethered acne scars caused by fibrotic bands beneath the skin. A clinical assessment helps determine suitability and whether combination therapy may improve results.
Subcision acne scar treatment is most effective when tailored to the individualโs scar type, degree of tethering and collagen response. A personalised assessment allows accurate identification of rolling, depressed and tethered acne scars, and determines whether combination therapy such as Rejuran Scar and polynucleotide-based regenerative treatment may enhance scar improvement.
Early treatment of structurally tethered scars can help improve skin texture, reduce scar depth and support long-term dermal remodelling.
To find out whether subcision acne scar treatment is suitable for your skin condition, a consultation is recommended.
Book a consultation here:
https://botoxsingapore.sg/contact-us/
The oral Wegovy pill has recently attracted significant attention following its overseas launch, particularly in the United States, where it has been evaluated for chronic weight management. As awareness of GLP-1โbased weight loss treatments continues to grow, many individuals in Singapore are now searching for information about this once-daily, needle-free oral option.
At present, however, the oral Wegovy pill is not yet available in Singapore, as local regulatory approval and supply pathways have not been finalised. This has led to increasing confusion between the oral Wegovy pill and other treatments such as oral semaglutide (Rybelsus), which is currently available locally under medical supervision.
https://botoxsingapore.sg/rybelsus-oral-semaglutide-singapore/
There is also growing interest in GLP-1โbased weight management options that are already available in Singapore, including once-weekly injectable formulations such as Wegovy injections.
https://botoxsingapore.sg/wegovy-weight-loss-singapore/
This page provides a practical overview of what the oral Wegovy pill is, its current availability status in Singapore and how it differs conceptually from other oral and injectable GLP-1 treatments.
The oral Wegovy pill is a once-daily oral medication containing semaglutide, developed as a GLP-1โbased treatment for chronic weight management. It is formulated as a tablet taken by mouth rather than an injection, offering a needle-free option within the same broader class of appetite-regulating medications.
This oral formulation has generated interest among individuals who are exploring medical weight loss options but prefer not to use injectable treatments.
The oral Wegovy pill belongs to a group of medications known as GLP-1 receptor agonists, which are used in medical settings to support appetite regulation and weight management. Semaglutide, the active ingredient, works within this class to influence hunger signals and food intake under medical supervision.
Unlike weekly injectable formulations, the oral version is designed for daily administration as a tablet.
One of the key distinctions of the oral Wegovy pill is its method of administration. Instead of a once-weekly injection, the medication is taken orally, which may be appealing to individuals who prefer tablet-based treatments or are uncomfortable with injections.
However, oral administration involves specific timing and absorption considerations that differ from injectable GLP-1 treatments and require adherence to prescribed instructions.
The oral Wegovy pill has been developed and evaluated for long-term weight management rather than short-term appetite suppression. It is intended to be used as part of a broader, medically supervised weight management approach that may include dietary guidance and lifestyle measures.
As with other prescription-based weight loss treatments, individual suitability and expected outcomes vary and should be assessed by a qualified healthcare professional.
At present, the oral Wegovy pill is not available in Singapore, as it has not yet received local regulatory approval. Although it has been launched overseas, including in the United States, availability in Singapore depends on regulatory review, approval processes, and supply arrangements that differ from those in other countries.
As a result, the oral Wegovy pill cannot currently be prescribed or dispensed locally, despite growing public interest and online discussion.
New medications are often introduced in selected countries before becoming available globally. An overseas launch, media coverage, or international approval does not automatically translate into availability in Singapore.
Local access depends on regulatory clearance, clinical guidelines, and distribution pathways specific to Singaporeโs healthcare system.
Individuals searching for the oral Wegovy pill in Singapore may encounter online advertisements or websites claiming to offer access to the medication. Such claims should be approached with caution, as unapproved sources may involve safety, authenticity, and regulatory risks.
Prescription-based weight management treatments should only be considered under proper medical supervision and through approved healthcare channels.
Regulatory approval ensures that medications meet established standards for safety, quality, and appropriate use within the local population. Until approval is granted, oral Wegovy should be regarded as unavailable for routine clinical use in Singapore.
Patients are advised to rely on medically verified information and consult qualified healthcare professionals regarding currently available weight management options.
The oral Wegovy pill and Rybelsus are closely related but they are not the same medication and are not used interchangeably. Although both contain the same active ingredient, semaglutide, they are developed, approved, and prescribed for different clinical purposes.
Understanding this distinction is important, as confusion between the two treatments is common, particularly among individuals searching for oral weight loss medications.
Both the oral Wegovy pill and Rybelsus contain semaglutide, a GLP-1 receptor agonist used in medical practice to influence appetite regulation and metabolic pathways. However, the oral Wegovy pill has been developed and evaluated specifically for chronic weight management.
Rybelsus, on the other hand, is approved for the management of type 2 diabetes. While weight changes may occur in some individuals using Rybelsus, its primary clinical purpose is blood sugar control rather than weight loss.
Although the underlying medication is the same, oral semaglutide is studied and used at different dose ranges depending on the intended indication. For weight management, higher daily doses have been evaluated overseas to support sustained appetite control and weight reduction.
Rybelsus is approved at lower daily doses that are intended to support glycaemic control. As a result, the magnitude and consistency of weight-related effects may differ between the two treatments.
Despite sharing the same active ingredient, oral Wegovy and Rybelsus are regulated, prescribed, and monitored differently. Differences in approved use, dosing intent, and clinical evaluation mean that one should not be substituted for the other without medical guidance.
Any discussion about oral semaglutide use should take place under medical supervision, with clear understanding of approved indications and local regulatory status.
The oral Wegovy pill works by targeting the bodyโs natural appetite-regulation pathways through glucagon-like peptide-1 receptor activation. Its mechanism of action is based on semaglutide, a GLP-1 receptor agonist that influences hunger signals, satiety, and digestive processes involved in energy intake.
When taken consistently under medical supervision, oral semaglutide supports reduced calorie consumption and gradual weight loss by acting on both central and peripheral pathways involved in appetite control.
GLP-1 receptors are present in key areas of the brain involved in hunger and satiety regulation. After absorption, oral semaglutide activates these receptors, helping to reduce hunger signals and promote earlier feelings of fullness during meals.
This central appetite-regulating effect plays an important role in lowering overall calorie intake without relying on stimulant-based appetite suppression.
By enhancing satiety signalling, the oral Wegovy pill may help individuals feel satisfied with smaller portions. This effect supports more controlled eating patterns and reduces the tendency for overeating during meals.
Satiety-related benefits typically develop progressively as treatment continues, rather than occurring immediately after the first dose.
GLP-1 receptor activation also slows gastric emptying, meaning food remains in the stomach for a longer period after eating. This contributes to prolonged feelings of fullness between meals and may reduce snacking frequency.
The effect on gastric emptying is dose-dependent and is one of the reasons gradual dose escalation is commonly used to improve tolerability.
Unlike injectable GLP-1 treatments, oral semaglutide has low natural bioavailability when taken by mouth. The tablet formulation and strict timing requirements are designed to optimise absorption through the gastrointestinal tract.
Correct administration plays a key role in ensuring consistent exposure to the medication and achieving the appetite-regulating effects observed in clinical studies.
The oral Wegovy pill has been evaluated in large-scale phase 3 clinical trials investigating once-daily oral semaglutide for chronic weight management. These studies were designed to assess treatment efficacy, safety profile, and durability of weight reduction when oral semaglutide is used under medically supervised conditions alongside structured lifestyle intervention.
Clinical trial data provides an important evidence base for understanding expected weight loss magnitude, treatment duration, and long-term sustainability in adults with overweight or obesity without diabetes.
Oral semaglutide for weight management was studied as part of the OASIS phase 3 clinical development programme. This programme evaluated once-daily oral semaglutide in adults with overweight or obesity who did not have diabetes, in combination with standardised dietary and lifestyle guidance.
The OASIS trials were designed to assess long-term weight outcomes, metabolic effects, and treatment tolerability over extended study durations, rather than short-term appetite suppression alone.
In the OASIS 4 trial, participants receiving higher-dose once-daily oral semaglutide experienced clinically meaningful weight reduction over approximately 64 weeks of treatment. Average weight loss in the active treatment group reached the low to mid-teens as a percentage of baseline body weight, depending on the statistical analysis applied.
In contrast, participants receiving placebo experienced substantially smaller changes in body weight over the same study period, demonstrating a clear treatment effect of oral semaglutide under controlled clinical conditions.
Beyond average weight reduction, the OASIS trials assessed the proportion of participants achieving predefined weight-loss thresholds commonly used in obesity research. A substantial proportion of individuals treated with oral semaglutide achieved at least 5% and 10% body weight reduction, with a smaller subset reaching higher thresholds.
These benchmarks are widely used in clinical practice as indicators of weight loss that may translate into meaningful improvements in metabolic and cardiovascular risk factors.
Weight reduction observed in the OASIS programme occurred progressively over the course of treatment rather than abruptly in the early weeks. This pattern is consistent with the appetite-regulating and energy intakeโmodulating mechanisms of oral semaglutide.
Sustained treatment under medical supervision was associated with maintenance of weight reduction throughout the study period, highlighting the importance of adherence, follow-up, and long-term planning when using prescription-based weight management therapies.
Oral GLP-1โbased weight management treatments have been studied in specific patient populations and are intended to be used under medical supervision. Suitability is determined by individual health status, weight-related risk factors, and the ability to adhere to treatment requirements rather than personal preference alone.
This section outlines the general profiles that have been evaluated in clinical studies and are commonly considered in medical practice.
Oral GLP-1โbased therapies have primarily been studied in adults with overweight or obesity, particularly where excess body weight contributes to health risks or affects overall wellbeing.
Individuals who have had difficulty achieving or maintaining weight reduction through lifestyle measures alone may be considered for prescription-based weight management following appropriate medical assessment.
Some individuals prefer oral medications due to discomfort with injections or a preference for tablet-based treatments. Oral GLP-1 formulations provide a needle-free alternative within the same medication class.
However, oral administration requires strict timing and fasting adherence, which should be discussed during consultation to ensure suitability.
Unlike weekly injectable GLP-1 treatments, oral formulations are taken once daily and require consistent administration conditions to optimise absorption.
Individuals who are able to maintain daily routines, follow fasting instructions, and attend regular follow-up appointments may be better suited to oral treatment approaches.
Not all individuals are suitable candidates for GLP-1 receptor agonist therapy. Medical history, existing conditions, and concurrent medications must be reviewed carefully to ensure safety.
A personalised medical consultation is essential to assess risks, expected benefits, and whether oral GLP-1โbased treatment is appropriate under local regulatory guidance.
In addition to controlled clinical trials, real-world data provides insight into how oral semaglutide performs in routine medical practice. Real-world outcomes reflect everyday use, where patients vary in adherence, lifestyle factors, and clinical follow-up intensity.
Observational data suggests that oral semaglutide can support clinically meaningful weight reduction in real-world settings, although results are typically more variable than those reported in phase 3 trials.
In real-world use, individuals taking oral semaglutide under medical supervision have commonly reported weight loss in the range of approximately 5โ10% of baseline body weight over 6 to 12 months of treatment.
Some individuals, particularly those able to tolerate higher doses and adhere closely to administration timing, may experience greater reductions, while others may see more modest changes depending on individual response and consistency.
Clinical trials such as OASIS are conducted under tightly controlled conditions, including structured lifestyle intervention, close monitoring, and strict adherence protocols. In everyday practice, variations in dosing consistency, meal timing, and follow-up frequency can influence outcomes.
As a result, real-world weight loss is often slightly lower than trial averages, though still clinically meaningful when treatment is used appropriately.
Because oral semaglutide has specific absorption requirements, real-world effectiveness depends heavily on correct administration. Taking the tablet on an empty stomach and delaying food intake afterward helps optimise absorption.
Patients who follow these instructions closely and attend regular medical follow-up tend to achieve more consistent appetite control and weight reduction.
Real-world observations are influenced by patient behaviour, tolerability, and individual metabolic differences. These outcomes should be viewed as general reference ranges rather than guaranteed results.
For this reason, real-world data is best interpreted alongside clinical trial evidence and personalised medical assessment.
One of the key differences between oral and injectable GLP-1 treatments lies in how the medication is absorbed. Unlike injections, which deliver semaglutide directly into the bloodstream, the oral Wegovy pill must pass through the gastrointestinal tract before reaching systemic circulation.
This unique absorption pathway explains why oral semaglutide has specific administration requirements and why its dosing strategy differs from injectable formulations.
Semaglutide is a peptide-based medication. Peptides taken orally are normally broken down by stomach acid and digestive enzymes before they can be absorbed, which historically made oral delivery of GLP-1 therapies impractical.
The oral Wegovy pill was developed to overcome this challenge by enabling semaglutide to be absorbed through the stomach lining before significant degradation occurs.
Oral semaglutide is co-formulated with an absorption enhancer known as sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, commonly referred to as SNAC. This compound plays a central role in enabling effective oral delivery of semaglutide.
SNAC works by creating a localised environment in the stomach that protects semaglutide from acidic degradation and facilitates its transport across the gastric mucosa into the bloodstream. This mechanism allows sufficient amounts of semaglutide to be absorbed to exert appetite-regulating effects.
Food and beverages can interfere with the absorption process by diluting the medication or altering gastric conditions. For this reason, the oral Wegovy pill is taken on an empty stomach, typically with a small amount of water, followed by a waiting period before eating, drinking, or taking other oral medications.
Adhering to these timing instructions helps maximise absorption consistency and supports more predictable treatment effects.
Even with the use of an absorption enhancer, only a small proportion of orally administered semaglutide enters systemic circulation. As a result, higher daily doses are required to achieve therapeutic exposure comparable to once-weekly injectable formulations.
This difference in bioavailability explains why oral Wegovy has been evaluated at higher milligram doses in clinical studies and highlights the importance of gradual dose escalation and medical supervision during treatment.
While oral GLP-1 treatments such as oral semaglutide can support meaningful weight reduction, some individuals may experience a slowing or plateau in weight loss over time. This does not necessarily indicate treatment failure and is a recognised phenomenon in medical weight management.
Understanding the common reasons behind weight loss plateaus helps set realistic expectations and supports appropriate adjustments under medical supervision.
Because oral semaglutide relies on precise administration conditions, even small deviations in timing, water volume, or fasting duration can reduce absorption. Inconsistent absorption may lead to reduced appetite control and slower weight loss progress.
Ensuring that the tablet is taken with minimal water and followed by an adequate fasting period before food or drinks is essential for maintaining treatment effectiveness.
As weight decreases, the body naturally adapts by adjusting energy expenditure and hunger signalling. This adaptive response can slow further weight loss despite continued treatment.
Such physiological changes are common across all forms of weight management and do not indicate that the medication has stopped working.
Some individuals may be unable to tolerate higher doses due to gastrointestinal side effects, which can limit the degree of appetite suppression achieved. Remaining at lower doses for extended periods may contribute to slower weight loss.
Dose adjustments should always be guided by medical assessment rather than self-directed changes.
Improved appetite control may still be offset by caloric compensation through energy-dense foods, liquid calories, or reduced physical activity. These factors can contribute to plateaus even when medication is taken correctly.
Ongoing lifestyle guidance plays an important role in supporting sustained weight reduction alongside pharmacological treatment.
When a plateau occurs, medical review allows clinicians to assess adherence, dosing, tolerability, and overall treatment strategy. Adjustments may include reinforcing administration technique, reviewing dietary patterns, or considering alternative approaches where appropriate.
Regular follow-up ensures that weight management remains safe, realistic, and aligned with individual health goals.
Unlike injectable GLP-1 treatments, the oral Wegovy pill has specific administration requirements that directly influence absorption and treatment effectiveness. These instructions are closely tied to how oral semaglutide is formulated and absorbed in the stomach.
Understanding and following these rules is essential for achieving consistent appetite regulation and predictable weight management outcomes.
Only a small fraction of orally administered semaglutide reaches systemic circulation, even when taken correctly. Small variations in timing, fluid intake, or stomach contents can significantly affect how much medication is absorbed.
Because of this limited bioavailability, strict adherence to administration instructions is necessary to maintain stable exposure over time.
The oral Wegovy pill is taken with only a very small amount of plain water, typically limited to one or two sips. Larger volumes of fluid may dilute the medication and interfere with the absorption process.
Using minimal water helps maintain the local stomach environment required for effective absorption of oral semaglutide.
After taking the oral Wegovy pill, a waiting period of at least 30 minutes is required before consuming anything else. This includes food, coffee, tea, supplements, and other oral medications.
This waiting period allows adequate time for semaglutide absorption to occur without interference from gastric contents or competing substances.
Injectable GLP-1 formulations bypass the gastrointestinal tract and deliver medication directly into the body, resulting in more predictable absorption and fewer timing constraints.
In contrast, oral semaglutide relies on precise stomach conditions for absorption, which is why administration timing and fasting requirements are more stringent.
Medical supervision helps ensure that administration instructions are clearly understood and followed correctly. Follow-up consultations allow clinicians to identify issues such as timing errors, inconsistent habits, or absorption-related variability.
Ongoing monitoring supports safer use, improved tolerability, and more consistent weight management results over time.
Oral and injectable GLP-1 receptor agonists belong to the same medication class but differ in how they are administered, absorbed, and used in clinical practice. Understanding these differences helps clarify why treatment protocols, dosing schedules, and patient suitability vary between oral and injectable options.
This section provides an educational overview of how oral and injectable GLP-1 treatments differ, without implying superiority of one approach over another.
Oral GLP-1 treatments are taken as tablets, typically on a once-daily basis, while injectable GLP-1 formulations are administered via subcutaneous injection, most commonly on a once-weekly schedule.
Differences in dosing frequency reflect how the medication is delivered into the body and how long it remains active, rather than differences in treatment intent.
Injectable GLP-1 treatments bypass the gastrointestinal tract and are absorbed directly into systemic circulation, resulting in more predictable bioavailability.
Oral GLP-1 treatments must pass through the stomach and rely on specialised formulation strategies to enable absorption, which introduces greater variability and necessitates strict administration instructions.
Oral GLP-1 treatments require precise timing, including fasting before and after dosing, minimal water intake, and separation from other medications or beverages.
Injectable treatments do not require fasting or timing adjustments related to meals, making administration more flexible for some individuals.
Both oral and injectable GLP-1 therapies typically involve gradual dose escalation to improve tolerability. However, oral formulations often require higher milligram doses due to lower bioavailability.
Individual tolerability, gastrointestinal side effects, and response to dose escalation vary and influence which approach may be suitable under medical supervision.
Choice of oral or injectable GLP-1 treatment depends on multiple factors, including patient preference, ability to adhere to administration requirements, medical history, and regulatory availability.
A personalised medical assessment is essential to determine which treatment approach aligns best with individual needs and expectations.
Safety is an essential component of any prescription-based weight management treatment. The oral Wegovy pill, like other GLP-1 receptor agonists, has a defined safety profile that has been evaluated in clinical trials conducted for chronic weight management using once-daily oral semaglutide.
Understanding potential side effects, precautions, and the importance of medical supervision allows individuals to make informed decisions while minimising unnecessary risks during treatment.
In clinical trials evaluating oral semaglutide for weight management, the most commonly reported side effects were gastrointestinal in nature. These included nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during the early phases of treatment or during dose escalation.
Such effects are consistent with the medicationโs mechanism of action on appetite regulation and gastric emptying and were generally reported to lessen over time as the body adjusted to treatment.
To improve tolerability and reduce the likelihood of side effects, oral semaglutide for weight management is typically introduced gradually rather than at full dose from the outset. Progressive dose escalation allows physiological adaptation and supports treatment continuation over the longer term.
Medical supervision plays an important role in adjusting dosing schedules, monitoring symptoms, and determining whether ongoing treatment remains appropriate based on individual response.
Not all individuals are suitable candidates for GLP-1 receptor agonist therapy. A thorough medical assessment is required to identify underlying conditions, risk factors, or contraindications that may affect safety.
Medical history, existing health conditions, concurrent medications, and previous reactions to GLP-1โbased treatments should be reviewed carefully before considering oral semaglutide.
Because the oral Wegovy pill influences appetite regulation, digestion, and metabolic pathways, ongoing medical monitoring is essential throughout treatment. Regular follow-up allows healthcare professionals to assess treatment response, manage side effects, and address any emerging concerns.
Prescription weight management therapies should always be used within a structured, medically supervised programme to ensure safety, appropriate dosing, and responsible long-term management.
This section addresses common questions that individuals frequently search for when researching the oral Wegovy pill, particularly in relation to weight management, availability, and how it differs from other GLP-1 treatments. The information below is provided for educational purposes and should not replace personalised medical advice.
Is the Oral Wegovy Pill Approved in Singapore?
At present, the oral Wegovy pill is not approved for prescription use in Singapore. Although it has been launched or evaluated overseas, including in the United States, local availability depends on regulatory approval processes specific to Singapore.
Until official approval is granted, oral Wegovy cannot be prescribed or dispensed locally.
Can the Oral Wegovy Pill Be Purchased Online or Imported?
Individuals may encounter online platforms claiming to sell or ship oral Wegovy internationally. Such sources should be approached with caution, as medications obtained outside approved healthcare channels may carry risks related to authenticity, safety, and legality.
Prescription-based weight management treatments should only be considered under proper medical supervision and through authorised healthcare providers.
Is the Oral Wegovy Pill Stronger Than Injectable Wegovy?
Oral and injectable Wegovy formulations contain the same active ingredient, semaglutide, but differ in how they are absorbed and dosed. Injectable formulations bypass the gastrointestinal tract and generally have more predictable absorption, while oral formulations require higher daily doses due to lower bioavailability.
These differences do not imply that one form is inherently stronger than the other, as treatment choice depends on formulation, dosing strategy, and individual response under medical supervision.
Why Must the Oral Wegovy Pill Be Taken on an Empty Stomach?
Oral semaglutide has low natural absorption when taken by mouth. The tablet formulation and strict fasting requirements are designed to optimise absorption through the stomach lining.
Taking the oral Wegovy pill with minimal water and waiting at least 30 minutes before consuming food, drinks, or other medications helps maximise the amount of medication absorbed.
Is the Oral Wegovy Pill the Same as Rybelsus?
Although both oral Wegovy and Rybelsus contain semaglutide, they are developed and regulated for different clinical purposes. Rybelsus is approved for the management of type 2 diabetes, while oral Wegovy has been studied specifically for chronic weight management.
Differences in approved indications and dosing strategies mean the two treatments should not be considered interchangeable.
When Might the Oral Wegovy Pill Become Available in Singapore?
There is currently no confirmed timeline for the approval or launch of the oral Wegovy pill in Singapore. Regulatory review processes vary by country and depend on local evaluation of safety, efficacy, and clinical use.
Individuals are advised to rely on officially approved treatment options and consult healthcare professionals for guidance while monitoring future regulatory developments.
Interest in the oral Wegovy pill has increased following overseas launches and publication of clinical trial data. However, regulatory approval and availability vary by country, and overseas access does not equate to local approval for prescription use in Singapore.
Understanding the current regulatory status is essential for individuals researching oral Wegovy as part of a medically supervised weight management plan.
At present, oral Wegovy is not approved for prescription use in Singapore. Local availability depends on regulatory review, approval processes, and supply arrangements, which have not yet been finalised.
As a result, oral Wegovy cannot be prescribed locally until official regulatory clearance is granted. Individuals should be cautious of online sources or overseas vendors claiming availability in Singapore.
Although oral Wegovy has been launched or discussed in overseas markets, regulatory approval is determined independently by each countryโs health authorities. Approval in one jurisdiction does not imply automatic availability elsewhere.
Singaporeโs regulatory framework evaluates medications based on local standards for safety, efficacy, and clinical use before approval is granted.
While oral Wegovy is not available locally, oral semaglutide in other approved formulations may be accessible in Singapore for specific indications. These formulations are regulated and prescribed under defined clinical contexts and should not be assumed to be equivalent to oral Wegovy.
Any use of oral semaglutide should be guided by a qualified healthcare professional, with clear understanding of approved indications and regulatory boundaries.
For individuals interested in medical weight management, treatment decisions should be based on options that are currently approved and available locally, rather than overseas availability alone.
A medical consultation allows for discussion of evidence-based alternatives, suitability, and long-term planning while monitoring ongoing regulatory developments.
CagriSema is currently under clinical evaluation and has not yet been launched or approved for routine clinical use in Singapore. While interest in this emerging combination weight loss injection continues to grow, individuals exploring medically supervised weight management options locally may wish to be aware of prescription-based treatments that are already available.
At present, commonly discussed medical weight loss injections and medications in Singapore include:
These treatments act on appetite-regulating pathways and are prescribed under medical supervision based on individual suitability.
CagriSema is an emerging injectable medication being studied for weight loss and appetite control. It is designed as a once-weekly injection that combines two appetite-regulating components into a single formulation, with the aim of influencing hunger, satiety, and eating behaviour more comprehensively.
Specifically, CagriSema combines a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, with a long-acting amylin analogue. These two components act on different but complementary hormonal pathways involved in appetite regulation, which is why CagriSema is often described as a combination weight loss injection.
Unlike many existing weight loss injections that rely on GLP-1 activity alone, CagriSema integrates both GLP-1-based appetite suppression and amylin-mediated satiety signalling. This dual-pathway approach is a key reason CagriSema has attracted attention as a potential next-generation injectable treatment for weight management.
At present, CagriSema remains under clinical evaluation and is not yet available for routine use in Singapore. Information about CagriSema is therefore based on research developments rather than widespread real-world treatment experience.
CagriSema is being developed as a prescription-based, once-weekly subcutaneous injection intended for medical weight management. Like other modern injectable weight loss treatments, it is designed for ongoing use rather than short-term appetite suppression.
If and when it becomes clinically available, appropriate medical assessment would be required to determine suitability, as CagriSema is not intended for cosmetic or over-the-counter use.
CagriSema is considered a combination weight loss injection because it contains two active components that influence appetite regulation through different mechanisms. Semaglutide acts through the GLP-1 pathway, which plays a role in reducing hunger and enhancing feelings of fullness.
The second component, an amylin analogue, affects satiety signalling and meal-related appetite control through additional pathways involved in how full a person feels during and after eating. By combining GLP-1 and amylin pathway effects into a single injection, CagriSema is being studied for its potential to provide broader appetite regulation than single-agent injections.
CagriSema has generated interest because it reflects a shift in how injectable weight loss treatments are being developed. Rather than relying on a single appetite-regulating mechanism, CagriSema combines multiple hormonal pathways involved in hunger and satiety into one formulation. This combination-based approach has positioned it as a potential next step in the evolution of medical weight loss injections.
As awareness of GLP-1โbased weight loss treatments has increased, attention has also expanded toward newer therapies that build upon these mechanisms. CagriSema is frequently discussed in this context because it integrates established GLP-1 activity with additional satiety signalling, which is why it is often described as a next-generation injectable under clinical evaluation.
In recent years, injectable weight loss treatments have become more widely recognised, both in medical practice and in public discussion. As understanding of how appetite-regulating hormones such as GLP-1 influence eating behaviour has grown, research has increasingly focused on whether combination approaches may offer more comprehensive appetite regulation.
CagriSema is commonly referenced in these discussions because it represents a combination strategy that reflects this broader research direction, rather than a completely new treatment category.
Current trends in medical weight management emphasise not only weight reduction, but also improved eating control, satiety, and long-term adherence. Newer injectable therapies are therefore being designed to influence multiple aspects of appetite regulation rather than short-term appetite suppression alone.
CagriSema fits into this evolving landscape by combining mechanisms that affect both hunger signalling and feelings of fullness. This alignment with broader treatment trends is one of the reasons CagriSema continues to attract attention, even while it remains under clinical evaluation and is not yet widely available.
CagriSema is often discussed in relation to other injectable weight loss treatments because it uses a combination formulation rather than relying on a single appetite-regulating pathway. Many established weight loss injections act through the glucagon-like peptide-1 (GLP-1) pathway alone, which plays a role in reducing hunger and increasing feelings of fullness.
CagriSema differs in that it combines a GLP-1 receptor agonist component, semaglutide, with a long-acting amylin analogue. These two components influence appetite regulation through distinct but complementary mechanisms, which is why CagriSema is frequently described as a combination weight loss injection under clinical evaluation.
Beyond biological mechanisms, differences between injectable weight loss treatments also relate to practical considerations such as dosing structure, tolerability, and how individuals respond over time. These factors contribute to why newer combination approaches continue to be explored in medical research.
Many currently available injectable weight loss treatments are based on GLP-1 receptor agonists, such as semaglutide, which act by slowing gastric emptying, enhancing satiety, and reducing appetite signals.
CagriSema builds upon this established GLP-1 approach by incorporating an amylin analogue. Amylin is a hormone involved in appetite regulation and satiety signalling, particularly in relation to meal size and feelings of fullness. By combining GLP-1 and amylin pathway effects into a single injection, CagriSema is being studied for its potential to provide broader appetite regulation than single-pathway injections.
Appetite regulation is influenced by multiple overlapping hormonal signals rather than a single pathway. GLP-1 and amylin affect different aspects of hunger, fullness, and eating behaviour, which has led researchers to explore whether combining these mechanisms may better reflect the complexity of appetite control.
CagriSema reflects this research direction by integrating semaglutide-based GLP-1 activity with amylin-mediated satiety signalling. This combination is one reason CagriSema is often referenced in discussions about the future development of injectable treatments for weight loss.
CagriSema is currently not available for routine clinical use in Singapore. It remains an investigational combination injectable medication that is still under clinical evaluation and has not yet received regulatory approval for prescribing locally.
Although CagriSema is increasingly discussed in relation to newer developments in injectable weight loss treatment, it is important to distinguish between therapies that are being studied in clinical research and those that are officially approved and accessible to patients in Singapore. Availability depends on regulatory review, safety evaluation, and alignment with local prescribing frameworks.
All prescription medications in Singapore must undergo a formal regulatory assessment process before they can be offered for clinical use. This process evaluates safety, effectiveness, appropriate indications, and safeguards for prescribing.
At present, CagriSema has not completed this regulatory process locally. As a result, it cannot be prescribed or dispensed in Singapore, and any discussion of its use remains informational rather than clinical.
Information about emerging weight loss injections such as CagriSema often appears online because clinical trial findings and research updates are shared internationally before regulatory approval is granted in specific countries.
Approval timelines can vary between regions due to differences in regulatory requirements and healthcare systems. As such, international discussions or media coverage about CagriSema do not indicate that it is currently accessible for treatment in Singapore.
While CagriSema remains under clinical evaluation and is not yet approved for use in Singapore, individuals exploring medical options for appetite control and weight management may wish to focus on treatments that are already available under prescription and medical supervision.
At present, established weight loss treatments in Singapore include injectable options such as Ozempic, Wegovy, and Mounjaro, as well as Rybelsus, an oral medication that acts on appetite-regulating pathways. These treatments differ in their mechanisms of action, dosing schedules, and suitability, and are prescribed based on individual medical assessment.
It is important to recognise the distinction between investigational therapies like CagriSema and approved prescription-based treatments. Understanding this difference helps manage expectations and supports informed decision-making while newer combination injections continue to progress through clinical research and regulatory evaluation.
As an emerging combination injectable therapy, CagriSema is still being evaluated in clinical research settings to better understand its safety profile, tolerability, and long-term effects. Like other prescription-based weight loss injections that act on appetite-regulating hormones, safety considerations form an important part of how CagriSema is studied and discussed.
Because CagriSema is not yet approved for routine clinical use in Singapore, available information is based on clinical trial data and ongoing research rather than widespread real-world prescribing experience. This makes careful interpretation of safety data essential.
Before any new injectable medication becomes available for clinical use, it undergoes multiple phases of clinical evaluation. These studies are designed to assess potential side effects, dosing tolerability, and how the medication affects different individuals over time.
For combination therapies such as CagriSema, safety evaluation also considers how the two active components interact within the body, particularly when influencing appetite, satiety, and gastrointestinal function. Findings from these studies help guide regulatory decisions and future prescribing frameworks.
Injectable weight loss treatments that act on appetite-regulating pathways are commonly associated with certain side effects, especially during early treatment phases or dose adjustments. Ongoing research into CagriSema continues to evaluate the type, frequency, and severity of side effects observed during clinical use.
Individual response to such treatments can vary based on factors such as baseline health, metabolic profile, and sensitivity to appetite-regulating hormones. This variability is an important focus of continued research.
Although CagriSema is still under investigation, its development highlights the broader principle that injectable weight loss therapies are intended for use under medical supervision. Clinical oversight allows for appropriate patient selection, monitoring of side effects, and adjustment of treatment strategies based on individual response.
As newer combination injections continue to be studied, medical supervision remains a key consideration in ensuring patient safety and responsible use once treatments become available.
Research into CagriSema is ongoing, with studies continuing to explore its safety profile, tolerability, and potential role within medical weight management. Results from these studies will inform whether and how CagriSema may eventually be integrated into clinical practice in different regions.
Until further regulatory decisions are made, information about CagriSema should be viewed as part of an evolving research landscape rather than established clinical guidance.
What Is CagriSema Used For?
CagriSema is being studied as an injectable medication for medical weight management in adults with overweight or obesity. It is designed to support appetite regulation and eating control through a combination of hormonal pathways and is not intended for cosmetic or unsupervised weight loss.
Is CagriSema a GLP-1 Weight Loss Injection?
CagriSema includes a glucagon-like peptide-1 (GLP-1) receptor agonist component, semaglutide, but it is not a single-agent GLP-1 injection. It also contains an amylin analogue, which acts on additional appetite-regulating pathways. This combination is what distinguishes CagriSema from GLP-1-only treatments.
How Is CagriSema Different From Ozempic or Wegovy?
CagriSema differs from GLP-1-only injections because it combines semaglutide with an amylin analogue. Ozempic and Wegovy act primarily through the GLP-1 pathway, whereas CagriSema is being studied as a combination therapy that influences appetite regulation through more than one mechanism.
CagriSema is still under clinical evaluation and is not currently available for routine use in Singapore.
Is CagriSema Available in Singapore?
No. CagriSema has not yet been launched or approved for routine clinical use in Singapore. Availability depends on regulatory approval and completion of clinical evaluation within the local healthcare framework.
Is CagriSema Safe?
The safety of CagriSema is being evaluated through ongoing clinical studies. As with other injectable weight loss treatments that act on appetite-regulating hormones, tolerability and side effects can vary between individuals. Medical oversight is essential for assessing safety if and when such treatments become available.
Who May Be Considered for CagriSema in the Future?
If approved in the future, CagriSema may be considered for adults with overweight or obesity as part of a medically supervised weight management programme. Suitability would depend on individual health factors, medical history, and response to other treatments.
Are There Alternatives While CagriSema Is Not Available?
Yes. Several prescription-based weight loss treatments are already available in Singapore under medical supervision. These include injectable options such as Ozempic, Wegovy, and Mounjaro, as well as Rybelsus, an oral medication. A medical consultation is required to determine suitability for these options.
Should I Wait for CagriSema or Consider Existing Treatments?
Whether to wait for emerging treatments or explore currently available options depends on individual health goals, medical profile, and preference. Understanding the differences between investigational therapies and approved prescription-based treatments can help guide informed decision-making.
Isotretinoin is a prescription oral retinoid widely regarded as one of the most effective medical treatments for persistent acne in Singapore. Understanding how it works helps patients appreciate why it remains a cornerstone in dermatology for long-term acne control and oil-regulation.
Isotretinoin reduces sebum production at the sebaceous glands, prevents clogged pores, decreases inflammation and helps normalise skin cell turnover. These combined actions target the root causes of acne rather than providing short-term surface relief.
Isotretinoin may be considered for patients with recurrent acne, nodules, inflammatory acne, acne that has not improved with conventional treatments, or acne that leaves marks and scars. It is also effective for individuals with excessively oily skin and large pores related to sebaceous gland overactivity.
Many patients in Singapore experience persistent acne due to humidity, active oil glands and genetic factors. Isotretinoin remains a frequently prescribed option because of its ability to reduce breakouts, improve skin texture and help minimise long-term acne scars.
Isotretinoin offers a range of clinically proven benefits for patients with persistent acne. This section outlines the key therapeutic effects that make isotretinoin one of the most effective long-term acne treatment options in Singapore.
Isotretinoin can significantly reduce the frequency, severity and recurrence of acne breakouts. Unlike conventional medications that work only while taken, isotretinoin targets the underlying factors contributing to acne development, allowing many patients to achieve extended periods of remission after completing a full course.
A major factor in acne formation is overactive sebaceous glands. Isotretinoin decreases the size and activity of these glands, resulting in visibly reduced oiliness. This improvement not only lessens the likelihood of clogged pores but also enhances overall skin texture and clarity.
By normalising the way skin cells shed within the pores, isotretinoin helps prevent the formation of new comedones. This reduces the cycle of repeated breakouts and allows the skin to heal more consistently throughout treatment.
Chronic or recurrent acne can lead to permanent scarring over time. By reducing inflammation and controlling new lesions from forming, isotretinoin decreases the risk of deep scarring, supporting better long-term skin quality and smoother complexion.
Many patients experience refinement of enlarged pores and a smoother overall skin surface. This secondary benefit arises from the decreased oiliness and reduced congestion within the sebaceous glands.
Although all isotretinoin brands contain the same active ingredient, many patients in Singapore search for treatment using specific commercial names. Including these terms helps clarify that they refer to the same medication used in doctor-guided acne management.
Accutane and Acnotin are widely recognised names for isotretinoin and are commonly searched by patients looking for information about acne treatment in Singapore. They contain identical active ingredients and function through the same oil-regulating and anti-inflammatory mechanisms.
Roaccutane is another well-known brand of isotretinoin, often referenced in older clinical discussions and patient forums. It works similarly to other isotretinoin formulations, providing long-term acne reduction by decreasing sebum production and minimising inflammation.
Oratane is commonly prescribed in many regions and is frequently mentioned by patients researching isotretinoin options. Its clinical effects and treatment protocols are consistent with other isotretinoin brands.
Nimegen is a generic isotretinoin brand used internationally and follows the same dosing principles as other formulations. Patients may encounter this name when comparing options or researching past experiences.
Several generic isotretinoin capsules are available globally. Regardless of branding, all versions rely on the same active compound to manage acne by reducing oil gland activity and improving long-term skin clarity.
Patients considering isotretinoin should undergo a structured medical evaluation to determine whether the treatment is appropriate based on acne severity, recurrence pattern, skin type and overall health status. This helps ensure safe prescribing, accurate dosing and strong long-term outcomes.
Isotretinoin may be considered for persistent, recurrent or treatment-resistant acne that has not responded adequately to topical therapies, oral antibiotics or medical-grade skincare. It may also be appropriate for individuals with acne that flares frequently, causes inflammation, or leaves long-term pigmentation or scarring. Patients with excessively oily skin may also benefit due to isotretinoinโs ability to reduce sebaceous activity.
Certain medical circumstances require caution or a different treatment approach. Isotretinoin is typically avoided during pregnancy, breastfeeding or in individuals planning to conceive soon. Patients with uncontrolled liver conditions, very high cholesterol or triglyceride levels, or those taking medications that may interact with isotretinoin will require further assessment before treatment. A detailed medical history helps determine suitability and ensures safe prescribing.
Before initiating isotretinoin, a doctor will review acne history, evaluate the skin, and perform baseline blood tests to assess liver enzymes and lipid profile. Repeat testing may be recommended during treatment depending on individual response, dosage and duration. This structured approach ensures that treatment is tailored safely and effectively to each patientโs needs.
A structured and medically supervised treatment plan helps ensure that isotretinoin is effective, safe and tailored to each patientโs skin condition, lifestyle considerations and long-term acne goals.
Isotretinoin dosing is customised based on factors such as body weight, acne severity, oil gland activity and previous treatment history. A personalised approach allows the doctor to optimise results while minimising the likelihood of side effects. Dosages may be adjusted progressively throughout the course as the skin responds.
Most patients undergo treatment for several months, with the exact duration depending on the cumulative dose required and the individualโs response. Some may complete their course earlier if acne stabilises rapidly, while others may require a longer regimen to achieve sustained clearance.
Regular reviews allow the doctor to monitor progress, assess skin changes and ensure treatment remains appropriate at each stage. Follow-up visits may include evaluations of oil regulation, breakout frequency, and any side effects that arise. Dosage adjustments are made when necessary to maintain effectiveness and safety.
Blood tests may be performed before starting treatment and periodically during the course to review liver function and lipid levels. Monitoring ensures that isotretinoin remains suitable and that any changes are identified early.
Patients commonly notice reductions in oil production within the first few weeks. Breakout frequency typically begins to decrease thereafter, with more significant improvements in texture and overall clarity observed as the treatment progresses. Cumulative dosing helps determine long-term remission potential.
Isotretinoin is a highly effective acne medication, but like all prescription treatments, it may cause certain side effects that vary in intensity from person to person. Understanding these possible effects helps patients set realistic expectations and recognise what is considered normal during therapy.
Several side effects are common during the early stages of isotretinoin treatment and are generally manageable with the appropriate skincare routine. These may include dry lips, dry skin, mild facial redness, temporary acne flare-ups, or increased skin sensitivity. Such symptoms typically improve as the skin adapts to the medication and can be alleviated with moisturisers, gentle cleansers and sun protection.
Some patients may experience less frequent effects such as dry eyes, dryness of the nasal passages, mild joint discomfort or transient headaches. These symptoms often relate to reduced oil secretion throughout the body. Adjusting the daily dose or incorporating supportive care measures can help minimise these effects.
Isotretinoin may occasionally influence liver enzymes or lipid levels. As part of safe prescribing practice, doctors may recommend periodic blood tests to assess liver function and triglyceride levels. These checks help ensure that any changes are promptly identified and addressed through dosage adjustments or supportive care.
While most side effects are mild and predictable, certain symptoms should be reviewed by a doctor without delay. These include persistent headaches, significant mood changes, severe abdominal discomfort or notable visual disturbances. Early evaluation ensures timely management and supports a safe, well-tolerated treatment course.
Isotretinoin is a highly effective acne medication, but its potency requires careful medical oversight and strict adherence to safety guidelines. Understanding these precautions helps ensure that treatment is both effective and well-tolerated throughout the course.
Isotretinoin is contraindicated during pregnancy due to the risk of birth defects. Patients who are pregnant, planning to conceive or not on reliable contraception should not start isotretinoin. Women of reproductive age are advised to use effective contraception and avoid pregnancy during treatment and for a period after completing the medication, as advised by their doctor.
Certain medications, supplements and skincare products may not be appropriate during isotretinoin therapy. Vitamin A supplements, high-dose retinoids, tetracycline-based antibiotics and abrasive topical treatments may increase the risk of irritation or adverse effects. Your doctor will review all current medications and skincare routines to ensure compatibility and avoid interactions.
Patients may need to adjust certain lifestyle habits while on isotretinoin. Alcohol consumption should be moderated due to potential effects on liver function. Prolonged sun exposure can increase skin sensitivity, so consistent sun protection is recommended. Activities that place stress on the skin, such as waxing or aggressive exfoliation, should also be avoided to prevent skin injury during treatment.
Completing a full isotretinoin course allows many patients to achieve long-lasting acne remission and significant improvements in oil regulation, skin texture and overall clarity. Understanding what results to expect helps set realistic treatment goals and provides clarity on the long-term benefits of therapy.
Patients often begin noticing reduced oil production within the first few weeks of treatment. Breakouts generally become less frequent and less inflamed as the course progresses. Most individuals observe clearer, more stable skin by the midpoint of therapy, with continued improvement as cumulative dosing increases.
One of the key advantages of isotretinoin is its ability to provide lasting acne control even after treatment stops. Many patients experience prolonged remission due to the reduction in sebaceous gland activity and improved skin turnover. The likelihood of long-term stability depends on factors such as cumulative dosage, skin type and hormonal influences.
Although most patients achieve satisfactory results after a single course, a small number may require a second round of treatment if acne recurs. This is more common in individuals with severe baseline oiliness, early onset acne or lower cumulative doses. A second course, if needed, is typically shorter and achieves good results.
After completing isotretinoin, maintaining clear skin may involve medical-grade skincare, non-comedogenic moisturisers, and targeted treatments such as chemical peels or lasers for residual pigmentation or scarring. A personalised post-treatment plan helps preserve the results and minimise the risk of new breakouts.
This FAQ section addresses the most common concerns patients have when considering isotretinoin in Singapore. Clear, evidence-based answers help patients understand how the treatment works, what to expect and how to prepare for a safe and effective course.
How Strong Is Isotretinoin Compared to Other Acne Treatments?
Isotretinoin is considered one of the most potent acne treatments available because it targets the key factors that drive acne formation: excessive oil production, clogged pores and inflammation. Unlike topical products or oral antibiotics that work only while used, isotretinoin offers the potential for long-term remission by reducing sebaceous gland activity at its root.
How Long Does It Take to See Results?
Initial improvements often appear within the first few weeks as oiliness gradually decreases. Acne lesions typically become fewer and less inflamed over the following months. Most patients achieve significant improvements by the midpoint of treatment, with clarity continuing to build as cumulative dosage increases.
Can Isotretinoin Cause Acne to Worsen Before It Improves?
Some individuals experience a temporary flare in the early stages of treatment as underlying congestion begins to surface. This is usually short-lived and stabilises as the medication starts regulating oil production and reducing inflammation.
Can I Do Facials or Laser Treatments During Isotretinoin?
Certain procedures, especially those involving exfoliation or skin resurfacing, may not be suitable due to increased skin sensitivity. Gentle treatments may be considered on a case-by-case basis. More intensive procedures, including some lasers, are typically postponed until after completing isotretinoin to reduce risks of irritation or delayed healing.
Do I Need to Avoid Exercise, Sun Exposure or Specific Foods?
Most patients can continue regular exercise unless joint discomfort arises. Increased sun sensitivity is common, so consistent sun protection is recommended. There are generally no strict dietary restrictions, although reducing alcohol intake may be advised due to the medicationโs impact on liver metabolism.
What Blood Tests Are Required During Treatment?
Baseline blood tests usually include liver enzyme evaluation and lipid profile assessment. Depending on individual response and dosage, follow-up tests may be performed throughout the course to ensure the medication remains safe and suitable.
What Should I Do If I Miss a Dose?
Missing an occasional dose is not usually problematic. Patients should simply take the next scheduled dose without doubling up. Maintaining consistent daily intake helps ensure that the cumulative dose targets are achieved.
Is It Safe to Take Isotretinoin Long-Term?
Isotretinoin is intended as a finite course rather than a long-term continuous medication. Treatment duration is typically several months, guided by cumulative dosage. Prolonged use beyond medically recommended durations is generally unnecessary and may increase side-effect risks.
Can Isotretinoin Permanently Reduce Oily Skin?
Many patients experience a significant long-term reduction in oiliness due to the shrinkage and regulation of sebaceous glands. While some oil production may gradually return after treatment, it often remains lower than pre-treatment levels.
What Steps Should I Take If Side Effects Occur?
Patients experiencing side effectsโwhether dryness, headaches or other symptomsโshould inform their doctor promptly. Adjustments in dosage, supportive skincare and additional monitoring may be implemented to ensure a comfortable and safe treatment course.
Book a Consultation for Acne Treatment in Singapore
A medical consultation ensures that every isotretinoin treatment plan is personalised, clinically appropriate and aligned with each patientโs long-term skin goals. Dr Edwin evaluates acne history, oil gland activity, previous treatments and overall health profile to determine whether isotretinoin, Accutane, Acnotin or other medical therapies are suitable and safe.
What to Expect During Your Consultation
During the consultation, Dr Edwin will review your acne pattern, assess any marks or scarring, evaluate oil production and discuss previous treatments that may have been ineffective. This structured assessment helps establish whether isotretinoin or alternative therapies would offer the best long-term outcome.
Individualised Treatment Recommendations
Based on your skin evaluation, Dr Edwin will outline a tailored management plan that may include isotretinoin, combination therapy or adjunctive procedures such as medical-grade skincare or acne lasers. Every recommendation is customised to optimise results while maintaining safety and comfort throughout the treatment course.
Schedule Your Appointment
Patients who would like a detailed evaluation can book a consultation directly with Dr Edwin. A personalised review ensures clarity, suitability and a comprehensive understanding of all available acne treatment options.
For appointments, please visit:https://botoxsingapore.sg/contact-us/
Orforglipron is an investigational oral GLP-1 receptor agonist developed by Eli Lilly as part of a new generation of therapies being studied for medically supervised weight management. Unlike once-weekly injectable GLP-1 medications currently used in clinical practice, Orforglipron is formulated as a once-daily tablet, offering a potential non-injectable option for individuals seeking appetite regulation and metabolic support through an oral route.
As a small-molecule GLP-1 compound, Orforglipron is designed to activate the GLP-1 receptor after gastrointestinal absorption, influencing satiety signalling, slowing gastric emptying and supporting post-meal glucose stability. This structure differentiates it from peptide-based GLP-1 injections and reflects global research efforts to expand accessibility for patients who prefer tablet-based therapy over injectable regimens.
A large Phase 2/3 international study published in November 2025 reported that more than 1,500 adults taking a 36 mg daily dose of Orforglipron achieved an average weight reduction of around 10 percent over 72 weeks, compared with roughly 2 percent among placebo participants. Improvements were also seen in metabolic markers such as insulin sensitivity and lipid balance. These outcomes have contributed to increasing interest in oral GLP-1 medication as a future approach to long-term weight management.
Orforglipron has not yet been approved for use in Singapore or any other country. Ongoing Phase 3 trials and subsequent regulatory reviews will determine future availability and its potential role within medical weight-loss programmes.
At present, the only approved oral GLP-1 option in Singapore is Rybelsus. Individuals may learn more about Rybelsus and other GLP-1 medications at the following links:
Rybelsus (Oral Semaglutide)
https://botoxsingapore.sg/rybelsus-singapore/
Ozempic (Semaglutide)
https://botoxsingapore.sg/ozempic-singapore/
Wegovy (Semaglutide 2.4 mg)
https://botoxsingapore.sg/wegovy-singapore/
Mounjaro (Tirzepatide)
https://botoxsingapore.sg/mounjaro-singapore/
Orforglipron is an oral GLP-1 receptor agonist being researched by Eli Lilly for its potential role in supporting medically supervised weight management. It belongs to a newer class of small-molecule GLP-1 compounds specifically engineered to be taken by mouth, allowing the medication to withstand digestion and activate GLP-1 receptors after absorption through the gastrointestinal tract.
Unlike traditional GLP-1 therapies that rely on peptide structures and require subcutaneous injections, Orforglipron is designed to function as a daily tablet. This makes it different from currently available GLP-1 treatments and reflects ongoing scientific efforts to expand the range of non-injectable options for long-term metabolic support.
The compound is being studied for its ability to trigger appetite-regulating pathways, influence satiety responses and support healthier glucose control. Researchers are also evaluating how its oral formulation may affect treatment adherence and suitability for individuals who prefer a tablet-based approach.
Although still in development and not yet available for prescription use, Orforglipron represents part of the growing interest in small-molecule GLP-1 medications that may eventually complement existing injectable solutions once regulatory approvals are completed.
Orforglipron works by activating the GLP-1 receptor, a key hormonal pathway involved in regulating appetite, fullness and metabolic balance. When the GLP-1 receptor is stimulated, the body naturally experiences reduced hunger signals, slower gastric emptying and improved post-meal glucose stability. These effects help decrease overall calorie intake and support long-term weight management.
As an oral small-molecule GLP-1 agonist, Orforglipron is formulated to deliver these metabolic effects through a once-daily tablet rather than a weekly injection. After being absorbed through the gastrointestinal tract, the medication interacts with GLP-1 pathways in the brain and digestive system, promoting sustained satiety and assisting with portion control throughout the day.
Clinical studies have shown that GLP-1 activation may help regulate eating behaviour, reduce cravings and improve glucose metabolism, which can be especially beneficial for individuals with metabolic risk factors. Researchers are also evaluating how Orforglipron affects energy expenditure, body-fat distribution and longer-term weight-maintenance outcomes.
While these mechanisms align with the general effects observed in GLP-1-based treatments, Orforglipron is distinct because it achieves this action via a daily oral dose. Ongoing clinical trials will determine how consistently and effectively its small-molecule design supports appetite regulation and metabolic health over extended treatment periods.
Orforglipron has undergone multiple early- and mid-stage clinical studies designed to evaluate its effectiveness, metabolic impact and overall tolerability as an oral GLP-1 therapy. These trials assess how a once-daily small-molecule GLP-1 agonist influences appetite control, glucose regulation and long-term weight-management outcomes.
In a large global Phase 2/3 study involving more than 1,500 adults with overweight or obesity, participants receiving Orforglipron at a daily 36 mg dose experienced an average weight reduction of approximately 10 percent over a 72-week treatment period. In comparison, those receiving placebo saw roughly 2 percent weight loss. The study also documented favourable changes in fasting glucose, insulin sensitivity, lipid markers and waist circumference, indicating broader metabolic improvements beyond weight reduction alone.
Earlier investigations showed dose-dependent effects, with higher Orforglipron doses producing more pronounced decreases in hunger levels and total caloric intake. Participants demonstrated steadier post-meal glucose responses and improvements in blood pressure and other cardiometabolic indicators.
Safety monitoring has shown that the most frequently reported side effects are gastrointestinal in nature, including nausea, diarrhoea and reduced appetite. These symptoms were generally mild to moderate and tended to lessen as patients continued treatment, following a pattern similar to other GLP-1โbased medications. Long-term safety findings will be defined once ongoing Phase 3 studies are completed and full data sets are available.
The results from these trials will guide regulatory decisions and determine Orforglipronโs future role within medically supervised weight-loss programmes in Singapore once approval is granted.
Orforglipron is not yet approved for prescription use in Singapore or any other global market. The medication is still progressing through late-stage Phase 3 clinical trials, which are required to establish long-term safety, metabolic outcomes and durability of weight-loss results. Until these studies are completed, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Singaporeโs Health Sciences Authority (HSA) cannot begin formal review.
Eli Lilly is expected to submit regulatory applications only after the full Phase 3 dataset is finalised. Based on current development timelines and typical approval pathways, Orforglipron is not anticipated to reach Singapore before 2026 or later, depending on international authorisations and the companyโs rollout strategy.
Patients in Singapore who are considering medical weight loss should rely exclusively on approved and licensed treatment options. Currently available GLP-1 therapies such as semaglutide and tirzepatide have undergone extensive evaluation and are legally prescribed under doctor supervision. These medications support appetite control, improved metabolic regulation and long-term weight reduction.
Any unregulated or grey-market Orforglipron products offered online should be avoided, as they have not been verified for safety, quality or authenticity. Individuals interested in medically supervised weight loss are advised to consult a licensed practitioner for proper evaluation, safe prescription options and ongoing monitoring.
Researchers are evaluating a range of potential benefits associated with Orforglipron as part of its ongoing Phase 3 development programme. As an oral GLP-1 receptor agonist, the medication is being investigated for its ability to influence appetite control, metabolic activity and long-term weight management through a once-daily tablet format.
Early clinical data suggests that Orforglipron may help reduce hunger signals and enhance satiety after meals, contributing to a measurable decrease in daily calorie intake. This appetite-regulation effect is a central feature of GLP-1โbased therapies and is being closely studied to determine how consistently an oral small-molecule agent can sustain these responses over extended treatment periods.
Researchers are also assessing the medicationโs impact on metabolic markers such as post-meal glucose control, insulin sensitivity and lipid balance. Improvements in these parameters may support healthier metabolic functioning in individuals with elevated cardiometabolic risk.
Additional areas of investigation include changes in waist circumference, blood pressure trends and body-composition patterns, such as reductions in visceral fat. These outcomes are important in determining Orforglipronโs potential role in long-term health management and its suitability as part of supervised obesity-treatment programmes.
As research continues, upcoming results from large-scale trials will clarify which benefits are consistent, clinically meaningful and sustainable, ultimately guiding how Orforglipron may be incorporated into future medical weight-loss frameworks once approved.
The safety profile of Orforglipron is still under active evaluation as ongoing Phase 3 trials continue to generate new data. Early studies indicate that its side-effect pattern may resemble that of other GLP-1 receptor agonists, particularly in relation to gastrointestinal tolerance during the initial stages of treatment.
The most frequently reported symptoms in clinical research include nausea, reduced appetite, diarrhoea and abdominal discomfort. These effects were generally described as mild to moderate and tended to lessen as participants continued therapy, reflecting physiological adaptation to GLP-1 receptor activity.
Some individuals also experienced transient vomiting, constipation or indigestion, with higher doses more commonly associated with stronger gastrointestinal reactions. Trial investigators are continuing to assess whether gradual dose-escalation schedules may help improve tolerability for patients who are sensitive to early treatment effects.
Beyond gastrointestinal symptoms, monitoring is ongoing for potential changes in heart rate, blood pressure and other metabolic indicators. Laboratory tests during trials also evaluate kidney and liver function to identify any concerns related to long-term use.
Because Orforglipron remains an investigational therapy, comprehensive safety conclusions cannot be made until full Phase 3 results are available. Patients considering medical weight-loss treatment should rely on approved therapies with established safety data and consult a licensed practitioner for individual assessment and monitoring.
While Orforglipron is still undergoing clinical evaluation and is not yet approved for public use, several medically supervised weight loss treatments are currently available in Singapore. These therapies work through scientifically established metabolic pathways and are prescribed based on individual health profiles, treatment goals and clinical suitability.
GLP-1โbased medications remain among the most effective pharmacological tools for appetite regulation and long-term weight management. Approved options available in Singapore include both injectable and oral formulations, each supporting reduced calorie intake, improved satiety and better glucose control under professional supervision.
Patients may explore the following doctor-prescribed treatments:
Ozempic (Semaglutide) โ Weekly GLP-1 Injection
https://botoxsingapore.sg/ozempic-singapore/
Wegovy (Semaglutide 2.4 mg) โ Chronic Weight Management Therapy
https://botoxsingapore.sg/wegovy-singapore/
Mounjaro (Tirzepatide) โ Dual GLP-1/GIP Weight Loss Injection
https://botoxsingapore.sg/mounjaro-singapore/
Rybelsus (Oral Semaglutide) โ Daily GLP-1 Weight Loss Pill
https://botoxsingapore.sg/rybelsus-singapore/
These medications are usually prescribed as part of a structured medical programme that includes proper assessment, dose adjustments and ongoing review to ensure treatment safety and effectiveness. Individuals who wish to learn more or explore eligibility may schedule a medical consultation at:
https://botoxsingapore.sg/contact-us/
Is Orforglipron Available in Singapore?
Orforglipron is not currently available in Singapore. The medication is still undergoing Phase 3 clinical trials and has not yet been submitted for regulatory approval. Its availability will depend on the completion of late-stage studies and subsequent review by agencies such as the U.S. FDA and Singaporeโs Health Sciences Authority (HSA). Current estimates suggest a possible launch no earlier than 2026.
How Much Weight Loss Has Been Reported in Studies?
In a large multinational Phase 2/3 study, participants taking a 36 mg daily dose of Orforglipron achieved an average body-weight reduction of around 10 percent over 72 weeks. The degree of weight loss varied with dose and individual metabolic factors. Further confirmation will come from ongoing Phase 3 trials.
How Does Orforglipron Support Weight Loss?
Orforglipron activates the GLP-1 receptor, helping regulate appetite, enhance satiety and stabilise post-meal glucose responses. These mechanisms contribute to reduced caloric intake and improved metabolic balance. The medication is designed as a once-daily oral small-molecule compound rather than a weekly injection.
What Side Effects Have Been Observed?
Early clinical data shows that gastrointestinal symptoms are the most common side effects. These may include nausea, abdominal discomfort, diarrhoea and reduced appetite. Such effects were typically mild to moderate and tended to improve as treatment continued. Long-term safety data is forthcoming from Phase 3 research.
When Might Orforglipron Be Released?
The earliest potential launch timeline is 2026 or beyond, depending on the outcomes of ongoing trials and regulatory decisions across major markets. Approval processes could extend this timeline further.
What Weight Loss Medications Are Already Approved in Singapore?
Current doctor-prescribed options include:
Ozempic (Semaglutide)
Wegovy (Semaglutide 2.4 mg)
Mounjaro (Tirzepatide)
Rybelsus (Oral Semaglutide)
These medications are available only under medical supervision and have established safety profiles supported by extensive clinical data.
Can I Pre-Register for Orforglipron Treatment?
No. Because Orforglipron is still in clinical development, pre-registration, pre-ordering or early reservation is not permitted. Patients wishing to stay updated can consult a licensed doctor for future updates.
Is Orforglipron Suitable for Long-Term Use?
Long-term suitability has not been established. Trials are currently assessing safety, metabolic changes and durability of weight-loss outcomes over extended treatment periods.
How Does Orforglipron Compare With Other Weight Loss Medications?
Direct comparisons cannot yet be made. While early data appears encouraging, its relative effectiveness versus established therapies such as semaglutide or tirzepatide will only be clear once more trial results are available.
Patients considering medically supervised weight loss may benefit from a personalised evaluation by Dr Edwin Lim, who will review weight history, metabolic markers, treatment suitability and any potential safety considerations before recommending an appropriate plan. This ensures that each therapy aligns with clinical guidance and long-term health objectives.
During the consultation, individuals can discuss doctor-prescribed options such as semaglutide, tirzepatide or oral GLP-1 therapy, as well as receive updates on emerging medications like Orforglipron as clinical data evolves. This helps patients make informed decisions while planning for both current and future treatment pathways.
Those who wish to explore a structured medical approach to weight management may arrange an appointment through the clinicโs contact page:
https://botoxsingapore.sg/contact-us/
Retatrutide is an investigational injectable therapy developed by Eli Lilly & Co. to explore new ways of addressing obesity and metabolic imbalance.
Unlike earlier medications that influence one or two hormone pathways, Retatrutide activates three โ GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon receptors โ to regulate appetite, energy expenditure and fat metabolism.
This triple-agonist approach is currently being studied for its potential to deliver broader metabolic outcomes compared with established GLP-1 and dual-agonist options such as Ozempic (Semaglutide) and Mounjaro (Tirzepatide).
In a Phase 2 trial published in The New England Journal of Medicine, participants using Retatrutide achieved an average weight reduction of roughly 24 percent over 48 weeks โ a significant result observed in early-stage research.
The treatment has attracted international media attention. Dazed Digital and Business Insider have referred to Retatrutide as the โGodzilla of weight loss injections,โ reflecting growing public curiosity about this next-generation compound. Despite the nickname, Retatrutide remains in clinical testing and is not approved for medical use.
Phase 3 studies are in progress to determine its long-term safety and efficacy. Although not yet available in Singapore, Retatrutide may become a future addition to doctor-supervised weight management once regulatory review is complete.
Retatrutide is a triple-agonist weight loss injection designed to target obesity and related metabolic conditions through multiple hormonal pathways.
It acts on GLP-1, GIP and glucagon receptors to assist in appetite control, glucose regulation and fat breakdown while helping preserve lean muscle mass. Clinical programmes are evaluating its efficacy, tolerability and long-term metabolic effects across diverse populations.
Retatrutideโs three-hormone targeting mechanism is intended to address multiple aspects of metabolism.
By integrating these pathways, Retatrutide aims to produce sustained weight reduction with balanced metabolic adaptation. Ongoing research will clarify how this triple-agonist design influences body composition and long-term results.
Following the success of earlier GLP-1 and dual-agonist agents, Eli Lilly developed Retatrutide as part of its metabolic research pipeline. Preclinical data suggested that activating three hormone receptors could enhance appetite control and energy use.
Subsequent human studies were launched in individuals with obesity and type 2 diabetes to verify these findings. The results of Phase 3 trials will determine its future clinical role once regulatory approval is pursued.
Phase 2 research has shown encouraging outcomes, with participants achieving average weight reductions of around 24 percent over 48 weeks. Improvement was also observed in fasting glucose, lipid profiles and blood pressure.
The most common side effects were transient gastrointestinal symptoms such as nausea and diarrhoea, which typically lessened as treatment continued. Large-scale Phase 3 studies are now under way to confirm these findings across broader populations.
Retatrutide is not yet available for prescription in Singapore or other markets. The medication is still under clinical evaluation and has not been approved by the U.S. FDA or Singaporeโs Health Sciences Authority (HSA). Based on current timelines, approval and local availability are expected after 2026.
For patients interested in safe, approved options, doctor-prescribed GLP-1 therapies such as Ozempic (Semaglutide), Wegovy (Semaglutide 2.4 mg), Mounjaro (Tirzepatide), and Rybelsus (Oral Semaglutide) are currently available in Singapore under medical supervision. Unverified or grey-market versions should be avoided for safety reasons.
Over the past decade, incretin-based treatments like semaglutide and tirzepatide have transformed the medical approach to obesity management. These medications act on GLP-1 or combined GLP-1/GIP receptors to help reduce appetite and improve metabolic health. Retatrutide builds upon this foundation by introducing additional glucagon receptor activity, which is under study for its potential to further enhance energy use and fat metabolism.
While existing treatments such as Ozempic, Wegovy, and Mounjaro are approved for use in Singapore, Retatrutide is still under investigation. Its development marks an important continuation of scientific efforts to refine and personalise future weight management therapies.
In Singapore, several clinically approved treatments are available under doctor guidance to help manage weight safely and effectively. They include:
These therapies are prescribed within structured programmes that include medical assessment, dose adjustment and ongoing review to ensure safety and effectiveness. Patients can book a consultation with Dr Edwin Lim at Edwin Lim Medical Aesthetic Clinic to learn more:
https://botoxsingapore.sg/contact-us/.
Is Retatrutide Available in Singapore?
No. Retatrutide is still under clinical evaluation and awaiting regulatory approval. Availability is expected after 2026 pending successful trial outcomes.
How Much Weight Loss Has Been Reported?
Phase 2 data showed average weight reductions of up to 24 percent over 48 weeks in participants with obesity or overweight.
How Does Retatrutide Work?
It stimulates GLP-1, GIP and glucagon receptors to help control appetite, improve insulin sensitivity and increase energy expenditure.
What Are the Common Side Effects?
Most reported effects are gastrointestinal (nausea, vomiting, diarrhoea) and tend to resolve as treatment continues. Long-term safety data are pending.
When Could It Be Launched?
Pending Phase 3 completion and regulatory review, launch may occur in 2026 or later.
Which Weight Loss Medications Are Currently Approved in Singapore?
Ozempic (Semaglutide) | Wegovy (Semaglutide 2.4 mg) | Mounjaro (Tirzepatide) | Rybelsus (Oral Semaglutide)
Can Patients Pre-Register for Retatrutide?
No pre-registration is available because the drug is still in the research phase. Patients can consult their doctor for updates and review current approved options instead.
If you are looking to buy Tirzepatide (a dual GLP-1 and GIP receptor agonist) in Singapore, it is important to know that this medication is only available under a doctorโs prescription. Unlike over-the-counter slimming products or online supplements, Tirzepatide is a clinically tested, prescription-only injection that must be dispensed in a licensed medical setting.
This next-generation treatment works by activating both GLP-1 and GIP pathways, giving it a more comprehensive effect on appetite control, blood sugar regulation, and fat reduction compared to older single-hormone injectables. For patients struggling with weight management, Tirzepatide has been internationally recognised as one of the most effective medical options available.
At our clinic, Tirzepatide is prescribed only after a thorough in-person consultation. This ensures the treatment is safe, personalised to your health profile, and supported with ongoing medical follow-up for best results.
Tirzepatide is a once-weekly injectable treatment designed to support weight management and improve metabolic health. Unlike older single-hormone medications, it targets two key pathways in the body โ GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
By acting on both hormones, it helps patients control appetite more effectively, regulate blood sugar, and sustain fat reduction over time.
Tirzepatide stands out from earlier injectables by combining two hormone pathways in one treatment. Clinical studies have shown that it can lead to significantly greater weight reduction compared to older GLP-1โonly medications. Many patients also report better appetite control and improved energy balance, making it one of the most advanced medical weight loss options currently available.
Yes. Tirzepatide is available in Singapore but only with a valid doctorโs prescription. It is not sold over the counter or online retail channels. Access is strictly regulated to ensure safe and appropriate use under medical supervision.
At our clinic, tirzepatide is prescribed as part of a structured weight management program. Every patient undergoes a detailed consultation before starting treatment, allowing the doctor to determine suitability, customise dosage, and provide ongoing follow-up. This ensures the treatment is both safe and effective.
Beginning treatment with tirzepatide requires an in-person medical consultation. This step is important to ensure that the medication is suitable for your health profile and that the treatment plan is tailored to your specific weight management goals.
Your doctor will review your medical history, current health status, and weight loss objectives. This forms the basis for deciding whether tirzepatide is the right option for you.
If you are a suitable candidate, a prescription will be issued. Your doctor will explain the starting dose, escalation schedule, and what to expect in the first few weeks.
Regular follow-up visits are scheduled to track progress, assess results, and address any side effects. This medical oversight ensures treatment remains safe and effective.
In addition to injections, your doctor may recommend lifestyle strategies such as nutrition adjustments or exercise plans to help maintain long-term results.
Tirzepatide offers a distinctive approach to medical weight loss by targeting two hormonal pathways at once. This dual action often translates to more effective appetite control and sustained fat reduction compared to older single-hormone injections.
By activating satiety signals in the brain, tirzepatide helps patients feel full sooner and stay satisfied with smaller portions.
The medication slows down gastric emptying, reducing hunger between meals and supporting more consistent dietary control.
Tirzepatide improves insulin sensitivity and lowers post-meal glucose spikes, benefiting both weight and metabolic health.
When combined with healthy lifestyle measures, tirzepatide encourages gradual, steady fat loss โ a more reliable approach than short-term dieting.
Tirzepatide is not a one-size-fits-all solution. It is a prescription-only injectable that must be recommended by a doctor after careful health evaluation. Generally, it may be suitable for adults who struggle with excess weight, appetite regulation, or metabolic issues that would benefit from medical support.
Individuals who fall within the overweight or obese range (based on body mass index) are often considered for Tirzepatide. In these cases, weight loss can provide significant improvements in overall health and wellbeing.
If frequent cravings, overeating, or difficulty maintaining portion sizes are major obstacles, Tirzepatideโs appetite-regulating mechanism may help restore balance.
Those with conditions such as type 2 diabetes, insulin resistance, or prediabetes may benefit from the dual-hormone action of Tirzepatide, which also supports healthier blood sugar regulation.
For people who have already attempted diet, exercise, or earlier single-hormone treatments with limited results, Tirzepatide offers a next-generation alternative that works through multiple metabolic pathways.
Like any prescription medication, Tirzepatide may cause side effects in some patients. These are usually mild, temporary, and improve as the body adjusts. Close medical supervision ensures that any issues are detected and managed early.
These effects are generally self-limiting and tend to lessen with continued use.
Although most patients tolerate Tirzepatide well, you should contact your doctor promptly if you experience:
Because Tirzepatide works on multiple metabolic pathways, ongoing monitoring is crucial. Regular check-ins with your doctor allow dosage adjustments, side effect management, and long-term support to ensure the treatment remains both safe and effective.
Tirzepatide is a prescription-only medication in Singapore. It cannot be purchased directly from retail pharmacies or online platforms. Access is restricted to licensed medical clinics, where a doctorโs consultation is required to confirm suitability and provide a prescription.
At our clinic, Tirzepatide is offered as part of a structured, doctor-supervised weight management program. This ensures that every patient receives:
Because Tirzepatide works on both GLP-1 and GIP pathways, careful medical oversight is essential to balance safety and effectiveness. Buying it through proper medical channels also guarantees authenticity, correct storage, and proper usage instructions.
If you are considering Tirzepatide as part of your weight management journey, the first step is to schedule an in-person consultation. This allows the doctor to review your health profile, determine suitability, and design a personalised treatment plan.
๐ Book your consultation today to begin safely under medical guidance.
Is Tirzepatide Available in Singapore?
Yes. Tirzepatide is available in Singapore under medical prescription. Internationally, it is marketed as Mounjaro, and it can only be dispensed after a consultation with a licensed doctor to ensure safety and suitability.
How Much Does Tirzepatide Cost in Singapore?
At our clinic, a 10 mg pen of Mounjaro (Tirzepatide) is priced at $898 before GST. Each pen contains a total of 40 mg of medication.
Who Is Suitable for Tirzepatide Treatment?
Suitability depends on your BMI, health history, and treatment goals. Adults who are overweight, obese, or have appetite regulation difficulties may be considered. Patients with related conditions such as type 2 diabetes or metabolic syndrome may also benefit. International studies with Mounjaro (Tirzepatide) have shown significant effectiveness in these groups.
What Results Can I Expect With Tirzepatide?
Many patients using Mounjaro (Tirzepatide) experience meaningful weight loss, improved appetite control, and better blood sugar regulation. Results vary depending on lifestyle factors and treatment adherence. Clinical trials with Mounjaro consistently showed greater weight reduction compared to earlier single-hormone injectables.
Is Tirzepatide Safe?
Mounjaro (Tirzepatide) is generally well tolerated. Common side effects may include nausea, mild stomach upset, or fatigue in the early weeks, which usually improve as the body adjusts. Regular doctor supervision ensures safe use and timely management of any side effects.
Where Can I Buy Tirzepatide in Singapore?
Tirzepatide cannot be purchased from retail pharmacies or online platforms. The only safe and legal way is through a doctorโs prescription. At our clinic, Mounjaro (Tirzepatide) is available as part of a structured medical program with full supervision.
Do I Need a Prescription for Tirzepatide in Singapore?
Yes. Mounjaro (Tirzepatide) requires a prescription and must be started only after an in-person medical consultation. This ensures that the correct dosage and treatment plan are tailored to your health profile.
How Is Tirzepatide Administered?
Mounjaro (Tirzepatide) is a once-weekly subcutaneous injection. Most patients begin at a lower starting dose, which can be increased gradually under doctor supervision. The injection pens are designed for ease of use, and your doctor will provide full instructions on proper administration.
How Long Does It Take to See Results?
Patients often notice appetite suppression within the first few weeks. However, significant weight loss usually develops over several months. International studies with Mounjaro (Tirzepatide) demonstrated continued improvements when treatment is maintained long term.
Can Tirzepatide Be Combined With Other Treatments?
In most cases, Mounjaro (Tirzepatide) is prescribed as a standalone injectable. It is best paired with lifestyle measures such as balanced nutrition and exercise. Combination with other injectable weight loss medications is not recommended unless advised by your doctor.
Do I Need to Change My Diet When Starting Tirzepatide?
While Mounjaro (Tirzepatide) helps reduce appetite and regulate blood sugar, long-term results are best achieved when paired with a balanced diet. Most patients find that smaller portions and healthier food choices become easier to maintain after starting treatment. Your doctor may also provide dietary recommendations tailored to your health profile.
How Does Tirzepatide Compare to Other Weight Loss Injections in Singapore?
Mounjaro (Tirzepatide) is considered a next-generation injectable because it activates both GLP-1 and GIP pathways. Earlier options typically act only on GLP-1. This dual action provides stronger appetite suppression, better blood sugar control, and often greater overall weight loss. International studies with Mounjaro (Tirzepatide) have consistently shown superior outcomes compared to older single-hormone injections.
Can Tirzepatide Be Used Long Term?
Yes, Mounjaro (Tirzepatide) can be prescribed as part of a long-term medical weight management plan. Many patients continue treatment for several months or longer, depending on their goals and health status. Regular follow-up consultations ensure that the dosage remains appropriate and that results are sustained safely over time.
ๆฐๅ ๅกไปฅ้ซๆฐดๅนณๅป็ๆๅกๅไธฅๆ ผ่ง่่็งฐ๏ผๆฏ่ฎธๅคไบบไฟก่ต็ๅฅๅบท็ฆ่บซ้ฆ้ใๆฌ่ฏๆไธๆณจไบๆไพGLP-1็ฑปๅ้ๆนๆก๏ผๅ ๆฌๆฏๅจไธๆฌกๆณจๅฐๅๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผใๅฉๆ้ฒ่ฝ๏ผไปฅๅๆฏๆฅๅฃๆๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผใGLP-1ๅไฝๆฟๅจๅๅญๅๅ ถๆพ่็ไฝ้็ฎก็ไฝ็จใๅฎๅ จๆงไธๅปๅญฆ็ๆๅจๆจ่๏ผๆไธบๅฝๅๅปๅญฆๅ่ฅ็ไธปๆต้ๆฉใๆไปฌ็ๅป็ๅข้ๅฐๆ นๆฎไธชไบบไฝ่ดจๅๅฅๅบท็ถๅต๏ผ้่บซๅฎๅถ็งๅญฆ็ฆ่บซๆนๆก๏ผ็กฎไฟๆฃ่ ๅจๅฎๅ จใไธไธ็็ฏๅขไธญ่ทๅพ็ๆณๅ้ไฝ้ชใ
GLP-1็ฑปๅ้ๆนๆกๅ ๅ ถ็งๅญฆๆงใๅฎๅ จๆงๅ้ซๆๆง๏ผๅทฒ็ปๆไธบ็ฐไปฃๅปๅญฆไฝ้็ฎก็้ขๅ็็ญ้จ้ๆฉใ็ธๆฏไผ ็ปๅ่ฅๆนๆณ๏ผGLP-1่ฏ็ฉ้่ฟ็ฌ็นๆบๅถๅธฎๅฉๆงๅถไฝ้๏ผๅนฟๆณๅบ็จไบๆฐๅ ๅกๆญฃ่งๅป็ไฝ็ณปใๆ ่ฎบๆฏๆฏๅจๆณจๅฐๅๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผ๏ผ่ฟๆฏๆฏๆฅๅฃๆๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผ๏ผ้ฝๆทฑๅๅธๆ็งๅญฆ็ฆ่บซไบบๅฃซ็้็ใไปฅไธๅฐ่ฏฆ็ป่งฃๆGLP-1ๅ่ฅๆนๆก็ๆ ธๅฟๆฆๅฟตใๅๆฌข่ฟๅๅ ๏ผไปฅๅไธไผ ็ปๅ่ฅๆนๅผ็ๅบๅซใ
GLP-1ๅไฝๆฟๅจๅๆฏไธ็ฑปๆจกไปฟไบบไฝ่ ้ๅคฉ็ถGLP-1ๆฟ็ด ็ๅคๆน่ฏ็ฉใๆๆฉ่ขซ็จไบ2ๅ็ณๅฐฟ็ ็่ก็ณๆงๅถ๏ผ่ฟๅนดๆฅๅ ๅ ถ่ฝๆๆๆๅถ้ฃๆฌฒใไฟ่ฟ้ฅฑ่ นๆๅนถๅปถ็ผ่ๆ็ฉบ๏ผ่ๅนฟๆณๅบ็จไบ่ฅ่ๅ่ถ ้็ฎก็ใๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผใไปฅๅๅฃๆๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผๅไธบ็ฎๅไธปๆต็GLP-1ๅ่ฅ่ฏ็ฉใ้็ๅฝ้ ไธดๅบ็ ็ฉถ่ฏๆฎไธๆญไธฐๅฏ๏ผ่ฟ็ฑป่ฏ็ฉๅจๆฐๅ ๅก็ญๅป็่ง่ไธฅ่ฐจๅฐๅบ๏ผๆไธบๅป็ๅ้็ๆ ธๅฟ้ๆฉไนไธใ
GLP-1็ฑป่ฏ็ฉไนๆไปฅๅๆฌข่ฟ๏ผๆฏๅ ไธบๅฎไปฌไธไป ่ฝๅค็งๅญฆใๅฎๅ จๅฐๅธฎๅฉ้ไฝไฝ้๏ผ่ฟ่ฝๆนๅๆฐ้ไปฃ่ฐขใ้ไฝ่ก็ณๅ่ฐๅฒ็ด ๆฐดๅนณ๏ผๆๆๅๅฐ่่ชๅ ็งฏใๅคง้็ ็ฉถๆพ็คบ๏ผๆฃ่ ๅจๅป็ๆๅฏผไธ่ง่ไฝฟ็จGLP-1่ฏ็ฉ๏ผๅนณๅๅฏๅจๆฐๆๅ ๅฎ็ฐๆพ่ไฝ้ไธ้ใๆญคๅค๏ผGLP-1่ฏ็ฉๅ ทๆ่ฏๅฅฝ็่ๅๆง๏ผๅคงๅคๆฐไบบ็พค่ฝๅฎๅ จ้ฟๆไฝฟ็จใๅฏนไบ้ฟๆๅ้ๆ ๆๆๅๅคๅๅผน็ไบบๅฃซ๏ผGLP-1ๆนๆกไธบๅปๅญฆๅ่ฅๆไพไบๅ จๆฐ้ๆฉใ
ไธไผ ็ป็่้ฃใ่ฟๅจใไปฃ้คใ็่ณ้ๅคๆนโ็ฆ่บซ่ฏโ็ธๆฏ๏ผGLP-1ๅ่ฅๆนๆกๆฅๆๆ็กฎ็็งๅญฆไพๆฎๅๅปๅญฆ็็ฎกใๅ ถๆบๅถ็ดๆฅไฝ็จไบไธญๆข็ฅ็ปๅ่ ้ๆฟ็ด ้่ทฏ๏ผ่ฝๅค่ช็ถ่ฐ่้ฃๆฌฒใๅปถ็ผ่ๆ็ฉบ๏ผ่้ๅ็บฏไพ่ตๆๅฟๅๆๅฑ้ฉๆๅใๆด้่ฆ็ๆฏ๏ผGLP-1่ฏ็ฉไธบไธชไฝๅๅ้ๆไพๅฏ่ฝ๏ผๅป็ไผๆ นๆฎๆฃ่ ๅ ทไฝไฝ่ดจๅๅฅๅบท็ถๅต้่บซๅถๅฎๅฎๅ จๆๆ็็ฆ่บซๆนๆกใ็ธๆฏไนไธ๏ผไผ ็ปๆนๆณๅธธๅธธๅ ้พไปฅๅๆๆๆๆๆ้่ๅๅคๅคฑ่ดฅ๏ผ็่ณๅธฆๆฅๅฅๅบท้ๆฃใ
GLP-1็ฑป่ฏ็ฉๆ นๆฎๆๅใ็จ่ฏๆนๅผๅ้ข็๏ผๅฏๅไธบๅค็ง็ฑปๅใไบ่งฃไธๅGLP-1่ฏ็ฉ็็น็น๏ผๆๅฉไบ้ๆฉๆ้ๅ่ช่บซ้ๆฑ็ๅฎๅ จๅ่ฅๆนๆกใไปฅไธๅฐๅๅซไป็ปๅไธปๆตGLP-1่ฏ็ฉ็็จๆณใไผๅฟๅ้็จไบบ็พค๏ผๅธฎๅฉๆจ็งๅญฆๅฏนๆฏๅๅณ็ญใ
ๆฏๅจๆณจๅฐไธๆฌก็ๅธ็พๆ ผ้ฒ่ฝ๏ผๆฏๅฝๅๆๅๆฌข่ฟ็GLP-1ๅ้่ฏ็ฉไนไธใๆญค็ฑป่ฏ็ฉ้่ฟๆๅไฝๅ GLP-1ๆฐดๅนณ๏ผๆๆๆงๅถ้ฃๆฌฒใๅขๅผบ้ฅฑ่ นๆ๏ผๅนถๅธฎๅฉ้ฟๆ็ปดๆไฝ้ใไธดๅบๆฐๆฎๆพ็คบ๏ผๅธ็พๆ ผ้ฒ่ฝ็ฑป่ฏ็ฉๅจๅปๅญฆไฝ้็ฎก็ๆน้ขๆๆพ่็ๆ๏ผไธๅฏไฝ็จ่พ่ฝป๏ผไฝฟ็จไพฟๆท๏ผ้ๅๅธๆ้ฟๆ็จณๆญฅๅ้็ไบบๅฃซใ
่ฏไนๅ่ฝๆฏไธ็งๆฏๅจๆณจๅฐไธๆฌก็ๆฐๅGLP-1/GIPๅๅไฝๆฟๅจๅ๏ผ็ฌ็นๆบๅถๅจไบๅๆถๆฟๆดปไธคๆกไปฃ่ฐข้่ทฏ๏ผๅฏน้ฃๆฌฒๆงๅถใไฝ้ๅ่ก็ณ็ฎก็ๅๆๆดๅผบ็ปผๅๆๆใ็ ็ฉถๅ็ฐ๏ผ่ฏไนๅ่ฝไธไป ่ฝๆๆพ้ไฝไฝ้๏ผ่ฟ่ฝๆๆๆนๅไปฃ่ฐข็ปผๅๅพ็ญ็ธๅ ณๅฅๅบท้ฎ้ข๏ผ้ๅ้ๅค้ไปฃ่ฐข็ฎก็็ๆฃ่ ใ
ๅฉๆ้ฒ่ฝๅฑไบๆฏๆฅๆณจๅฐ็GLP-1ๅไฝๆฟๅจๅ๏ผไผ ็ปไธ็จไบ็ณๅฐฟ็ ๅไฝ้็ฎก็ใ่ฏฅ่ฏ็ฉ้ๅ้ๅป็ๆ นๆฎไธชไฝๅๅบ็ตๆดป่ฐๆดๅ้็ๆฃ่ ๏ผๅฏนไน ๆฏไบๆฏๆฅ็จ่ฏๅนถ้่ง่ฏ็ฉๅฎๅ จๆง็ไบบ็พคๅ ทๆ่พๅคงๅธๅผๅใ
ๆฏๆฅๅฃๆ็ๅธ็พๆ ผ้ฒ่ฝ็๏ผไธบไธๅๆฌขๆ้็ๆฃ่ ๆไพไบๅ จๆฐ้ๆฉใๆญค่ฏ็ฉๅๆ ท่ฝๅคๆจกๆไฝๅ GLP-1ๆฟ็ด ็ไฝ็จ๏ผ่พพๅฐๆๅถ้ฃๆฌฒใ้ไฝไฝ้็็ฎ็ใไฝฟ็จๆนไพฟใไพไปๆงๅฅฝ๏ผ้ๅธธ้ๅๅฏนๆณจๅฐๆๆๆ็ๆดป่ๅฅ่พๅฟซ็็จๆทใ
ไธๅGLP-1่ฏ็ฉๅจ็ๆใ่ๅๆงใไฝฟ็จไพฟๆทๆงๅ้็จไบบ็พคไธๅญๅจๅทฎๅผใไธ่ฌ่่จ๏ผๆฏๅจๆณจๅฐๅ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝ๏ผๆด้ๅ่ฟฝๆฑ้ฟๆ็จณๅฎ็ฆ่บซๅ็ๆดป่งๅพ็ไบบๅฃซ๏ผๆฏๆฅ็จ่ฏๅ๏ผๅฆๅฉๆ้ฒ่ฝใๅฃๆๅธ็พๆ ผ้ฒ่ฝ็๏ผ้ๅ้่ฆไธชๆงๅ่ฐๆดๆไธไพฟๆฏๅจๅ่ฏ็ๆฃ่ ใๅ ทไฝ้ๆฉๅบ็ฑไธไธๅป็่ฏไผฐไธชไบบไฝ่ดจใๅฅๅบท็ถๅตๅ็ๆดปไน ๆฏๅๅๅบ็งๅญฆๅปบ่ฎฎใ
GLP-1็ฑป่ฏ็ฉไฝไธบๆฐไธไปฃๅปๅญฆๅ่ฅๅทฅๅ ท๏ผๅนถ้ๆๆไบบ้ฝ้ๅใ็งๅญฆ็ญ้้ๅบ็ๅๅ็่ฏไผฐ็ฆๅฟ็๏ผๆฏ็กฎไฟ็ๆไธๅฎๅ จ็ๅบ็กใๆ ่ฎบๆฏๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผ่ฟๆฏๅฃๆๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผ๏ผๅจๆฐๅ ๅกไฝฟ็จๅๅ้ไธไธๅป็่ฏไผฐใไปฅไธๅฐ่ฏฆ็ป่งฃๆ้ๅไบบ็พคใ้ๅบ็ใ็ฆๅฟ็ๅๆฒป็ๅ็ๅๅคๅทฅไฝ๏ผๅธฎๅฉๆจ็งๅญฆใๅฎๅ จๅผๅฏๅ้ไน่ทฏใ
ๆ ่ฎบๆฏๆฏๅจๆณจๅฐๅๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผ๏ผ่ฟๆฏๆฏๆฅๅฃๆ็ๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผ๏ผ่ฟ็ฑปGLP-1่ฏ็ฉไธ่ฌ้ๅไฝ้ๆๆฐ๏ผBMI๏ผโฅ27็่ถ ้ๆ่ฅ่ๆๅนดไบบใๅฐคๅ ถ้็จไบๅคๆฌกไผ ็ปๅ่ฅๅคฑ่ดฅใๆๅๅผน๏ผๆไผดๆ่่ช่ใ้ซ่กๅใ้ซ่ก่็ญไปฃ่ฐขๅผๅธธ็ไบบๅฃซใๅฏนไบ็ๆดป่ๅฅๅฟซใ้ฅฎ้ฃไธ่งๅพใ้พไปฅ้ฟๆๅๆ่ฟๅจ็ไบบ็พค๏ผGLP-1ๅปๅญฆ็ฆ่บซๆนๆกๅจๅป็ๆๅฏผไธๆดๆๅๅพ็งๅญฆใๆไน ็ๆๆใ
ๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผๅๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผ็ญGLP-1่ฏ็ฉ๏ผๅธธ็จไบๅ็บฏๆง่ฅ่ใไปฃ่ฐข็ปผๅๅพใ่ฅ่็ธๅ ณ้ซ่กๅๆ่ก่ๅผๅธธใไปฅๅ็ณ่้ๅผๅธธ็ญไบบ็พคใๅป็ไผๆ นๆฎไธชไบบๅฅๅบท็ถๅตใๆ ขๆง็พ็ ใๆขๅพๅ้็ปๅไธ็จ่ฏๅฒ๏ผ่ฟ่กไธชๆงๅ่ฏไผฐ๏ผ้ๆฉๆ้ๅ็GLP-1่ฏ็ฉ็ฑปๅๅๆนๆก๏ผ็กฎไฟ็จ่ฏ็็งๅญฆๆงไธๅฎๅ จๆงใ
ๅฏนไบๅญๅฆใๅบไนณๆๅฅณๆงใ็ฒ็ถ่ บ้ซๆ ท็ๅฎถๆๅฒใ้ๅบฆๆถๅ้็พ็ ใไธฅ้่่พๅ่ฝ้็ขๆๆขๅพGLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผ่ฟๆๅฒ่ ๅไธบ็ฆๅฟใ18ๅฒไปฅไธ้ๅฐๅนดใ70ๅฒไปฅไธ่ไบบใ่ฎกๅๆๅญๆๆฃๆ็นๆฎๆ ขๆง็พ็ ็ๆฃ่ ๏ผๅจ่่ไฝฟ็จGLP-1่ฏ็ฉ๏ผๅฆๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ็ชๆฉไฝณ็ญ๏ผๅ๏ผๅฟ ้กป็ฑๅป็ไธฅๆ ผ่ฏไผฐๅๆๅ ณ๏ผ็กฎไฟ้ฃ้ฉๅฏๆงใ
ๅจๆญฃๅผๅผๅงGLP-1็ฑป่ฏ็ฉ๏ผๅ ๆฌๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ่ฏไนๅ่ฝใ็ชๆฉไฝณใ่ฏบๅ่พพ็ญ๏ผๅ้ๆนๆกๅ๏ผๅป็ไผๅ จ้ข่ฎฒ่งฃๆฒป็ๆต็จใๅ้่ฐๆดๅๅใๅฏ่ฝๅบ็ฐ็ๅฏไฝ็จๅๆณจๆไบ้กนใ็กฎไฟๆฃ่ ๅ ๅ็่งฃๆดไธชๅปๅญฆๅ้่ฟ็จ๏ผ็งๅญฆใ่ง่็ๅๆๅๅคไธ็ฅๆ ๅๆ๏ผๆฏๅฎ็ฐ็ๆณไฝ้็ฎก็ๅ็จ่ฏๅฎๅ จ็ๅบ็กใ
ๅจๆฐๅ ๅก๏ผGLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ่ฏไนๅ่ฝใ็ชๆฉไฝณๅ่ฏบๅ่พพ๏ผๅนฟๆณ็จไบๅปๅญฆๅ้๏ผๆๆ่ฏ็ฉๅ้ไธไธๅป็่ฏไผฐไธๆญฃ่งๅคๆน๏ผๅนถ็ฑๅป็ๅ จ็จ็ฎก็ใ่ง่ๅ็ๆฒป็ๆต็จๅไธฅๆ ผ็็จ่ฏ็ฎก็ๆ ๅ๏ผไฟ้ๆฏไฝๆฃ่ ๅจๅฎๅ จ็ฏๅขไธญ็งๅญฆๅ้ใไปฅไธๅฐไป็ปไธปๆตGLP-1่ฏ็ฉๅ้ๆนๆกๅจๆฐๅ ๅก็ๆต็จใๅ่งไธๅธธ่งๅฎๅ จ็ฎก็้็นใ
GLP-1ๅ้ๆฒป็้ฆๅ ้่ฆๅป็ไธๆฃ่ ๆทฑๅ ฅๆฒ้๏ผไบ่งฃๆขๅพไฝ้็ฎก็็ปๅๅๅฅๅบท็ถๅตใๆ นๆฎไธชไบบ้ๆฑๅ็จ่ฏไน ๆฏ๏ผๅป็ไผๅปบ่ฎฎๆ้ๅ็ๆนๆก๏ผไพๅฆๆฏๅจๆณจๅฐๅๅธ็พๆ ผ้ฒ่ฝ๏ผๅ ๆฌๅฅฅ่ตๆฎๆ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผ๏ผๆๆฏๆฅๅฃๆ็่ฏบๅ่พพใไธชๆงๅๆๅฏผ็กฎไฟ่ฏ็ฉ้ๆฉไธ็จ่ฏ่ฟ็จ่ดดๅๅฎ้ ้ๆฑ๏ผๆๅๅ้ไฝ้ชๅๅฎๅ จๆงใ
ๆ ่ฎบ้ๆฉๅช็งGLP-1่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝๆ่ฏบๅ่พพ๏ผ๏ผ้ฝๅฟ ้กป็ฑๆณจๅๅป็ๅผๅ ทๅคๆน๏ผๅนถๅจๅป็็็ฃไธ่ง่็จ่ฏใๆฃ่ ไธๅฏ่ช่ก่ดญไนฐ๏ผไนไธๅฏ้่ฟ็ฝ็ปๆๅ ถไป้ๆญฃ่งๆธ ้่ทๅพใๅป็ไผ่ฏฆ็ป่ฏดๆๆฏ็ง่ฏ็ฉ็ไฝฟ็จๆนๅผใๅ้่ฐๆด่ฆ็นๅ็็จๅฎๆ๏ผ็กฎไฟๆฒป็่ฟ็จๅฎๅ จๅ่งใ
ๆดไธชๆฒป็ๆ้ด๏ผๅป็ไผๅฎๆ้่ฎฟ๏ผๅ ณๆณจไฝ้ๅๅๅ่ฏ็ฉๅๅบใไพๅฆ๏ผไฝฟ็จๆณจๅฐๅๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผๆ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผ็ๆฃ่ ๏ผๅป็ไผๆ นๆฎๆฏๆฌกๅ้ฆ่ฐๆดๆนๆก๏ผ่้ๆฉ่ฏบๅ่พพ็็จๆท๏ผไนไผ่ทๅพ็จ่ฏไพไปๆงๅๆๆ็ๆ็ปญ่ท่ฟใ่ฟ็งๅจๆ็ฎก็ๆๅฉไบๆๅ็ๆ๏ผๅๆถๅๆถๅ็ฐๅ่งฃๅณๅฏ่ฝๅบ็ฐ็้ฎ้ขใ
GLP-1่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผๅจๅปๅญฆๆๅฏผไธๆดไฝๅฎๅ จๆง้ซใๅธธ่ง่ฝปๅบฆๅฏไฝ็จๅ ๆฌๆถๅฟใ่ น่ๆ่ นๆณป๏ผๅป็ไผ็ปๅๅ ทไฝ่ฏ็ฉๅไธชไบบไฝ่ดจๅปบ่ฎฎๅ้็ๅ้่ฐๆดๅๅบๅฏนๆชๆฝใ่ฅๅบ็ฐ็ฝ่งๆ่พ้็ไธ่ฏๅๅบ๏ผๆฃ่ ๅบๅๆถๅฐฑๅป๏ผ็ฑๅป็่ง่ๅค็๏ผ็กฎไฟๆดไธชๅ้่ฟ็จ็ๅฎๅ จๆงใ
้็ๅปๅญฆ็ ็ฉถ็ไธๆญๆทฑๅ ฅ๏ผGLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใใๅธ็พๆ ผ้ฒ่ฝ็ใ่ฏบๅ่พพใ็ญ๏ผๅจไฝ้็ฎก็้ขๅ็ไธดๅบ็ๆๅทฒ็ปๅพๅฐๅ จ็ๅ ฌ่ฎคใๅคง้ๅฝ้ ๆๅจไธดๅบ่ฏ้ชๅๅปๅญฆๆ็ฎๆพ็คบ๏ผGLP-1ๅไฝๆฟๅจๅไธไป ๅฏไปฅๆๆ้ไฝไฝ้๏ผ่ฟ่ฝๆนๅไปฃ่ฐข็ปผๅๅพ็ญๅค็งๅฅๅบท้ฃ้ฉใไธๆๅฐ่ฏฆ็ป่งฃ่ฏปGLP-1ๅ้็็งๅญฆไพๆฎใไธป่ฆ็ ็ฉถๆๆๅ็ๆๅฝฑๅๅ ็ด ๏ผๅธฎๅฉๆจๅ จ้ขไบ่งฃ่ฏฅๆนๆก็ๅฎ้ ่กจ็ฐใ
ๅค้กนๅฝ้ ๅคงๅไธดๅบ็ ็ฉถ่ฏๅฎ๏ผๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผๅ่ฏบๅ่พพ็ญGLP-1็ฑป่ฏ็ฉๅฏๅธฎๅฉ่ถ ้ๅ่ฅ่ๆฃ่ ๅจ3-6ไธชๆๅ ๅฎ็ฐ5%~15%็่ณๆด้ซ็ไฝ้ไธ้ใไธดๅบๆฐๆฎๆพ็คบ๏ผๅคงๅคๆฐๆฃ่ ๅจๅป็ๆๅฏผไธ่ง่ไฝฟ็จGLP-1่ฏ็ฉ๏ผ่ฝๅคๆ็ปญๅๅฐ้ฃ้ใๅขๅผบ้ฅฑ่ นๆ๏ผๅนถๆพ่้ไฝ่ ฐๅดๅไฝ่ๆฏไพใ็ ็ฉถ่ฟๅ็ฐ๏ผ่ฟไบ่ฏ็ฉๅจ่ก็ณ่ฐๆงใ่ก่ๆนๅ็ญไปฃ่ฐขๆน้ขไนๅ ทๆ็งฏๆไฝ็จใ
ๅฐฝ็ฎกGLP-1็ฑป่ฏ็ฉๆดไฝๅ้ๆๆๆพ่๏ผไฝ็ๆๅๅค็งๅ ็ด ๅฝฑๅ๏ผๅฆ็จ่ฏไพไปๆงใไธชไฝไปฃ่ฐขๅทฎๅผใ้ฅฎ้ฃๅ่ฟๅจ้ ๅ็ญใ้จๅๆฃ่ ๅจๆฒป็ๅๆไฝ้ไธ้ๆดๅฟซ๏ผ่ๆไบไบบๅ้ๆด้ฟๆถ้ดๆ่ฝ็ๅฐๆๆพๆๆใ็งๅญฆ็ ็ฉถๅผบ่ฐ๏ผๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผๅ่ฏบๅ่พพ็ๆไฝณ็ๆๅพๅพ้่ฆๅจๅป็ๆ็ปญ้่ฎฟใๅฎๆ่ฐๆดๆนๆกๅๆฃ่ ็งฏๆ้ ๅไธๅฎ็ฐใ้ๆฉ็งๅญฆ็็ๆดปๆนๅผใๅๆๅปๅญฆๆๅฏผ๏ผๆฏไฟ่ฏ้ฟๆๆๅ็ฆ่บซ็ๅ ณ้ฎใ
ๅฝๅๅปๅญฆๅ่ฅ้ขๅๅธธ็จ็GLP-1็ฑป่ฏ็ฉๅ ๆฌๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผๅๅฃๆๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผใไธๅ่ฏ็ฉๅจๆๅใ็จๆณใ้็จไบบ็พคๅ็ๆ่กจ็ฐไธๅๅญๅจไธๅฎๅทฎๅผใไปฅไธๅฐไป่ฏ็ฉๆๅใไฝ็จๆบๅถใ็จ่ฏๆนๅผใ็ๆๅฎๅ จๆงๅ้ๅไบบ็พค็ญๆน้ข่ฟ่กๅ จ้ขใๅฎข่ง็ๅฏนๆฏๅๆ๏ผๅธฎๅฉๆฃ่ ็งๅญฆ้ๆฉ้ๅ่ช่บซ้ๆฑ็GLP-1ๅ้ๆนๆกใ
| ่ฏ็ฉๅ็งฐ | ไธป่ฆๆๅ | ๅๅ/็จๆณ | ็ป่ฏ้ข็ | ไฝ็จๆบๅถ | ้็จไบบ็พค | ไธป่ฆๅฏไฝ็จ |
| ๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผ | ๅธ็พๆ ผ้ฒ่ฝ | ็ฎไธๆณจๅฐ | ๆฏๅจไธๆฌก | GLP-1ๅไฝๆฟๅจๅ๏ผๆๅถ้ฃๆฌฒใๅปถ็ผ่ๆ็ฉบ | ้่ฆ้ฟๆไฝ้็ฎก็๏ผ้ๅๅฎๆ้่ฎฟ็ๆฃ่ | ๆถๅฟใ่ น่ใ่ นๆณป |
| ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผ | ่ฏไนๅ่ฝ | ็ฎไธๆณจๅฐ | ๆฏๅจไธๆฌก | GLP-1/GIPๅๅไฝๆฟๅจๅ๏ผๆๅถ้ฃๆฌฒใๅ้ไปฃ่ฐข่ฐ่ | ้ๅค้ไปฃ่ฐข็ฎก็ใๅธๆๆณจๅฐๆนๆก็ๆฃ่ | ๆถๅฟใ่ นๆณปใ้ฃๆฌฒๅ้ |
| ๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผ | ๅธ็พๆ ผ้ฒ่ฝ | ๅฃๆ็ๅ | ๆฏๆฅไธๆฌก | GLP-1ๅไฝๆฟๅจๅ๏ผๆๅถ้ฃๆฌฒใๅปถ็ผ่ๆ็ฉบ | ไธๆนไพฟๆณจๅฐใๅธๆๅฃๆ็จ่ฏ็ๆฃ่ | ๆถๅฟใ่ น่ใ่ นๆณป |
ๅจไฝฟ็จGLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใใๅธ็พๆ ผ้ฒ่ฝ็ใ่ฏบๅ่พพใ๏ผ่ฟ่กๅปๅญฆๅ้ๆถ๏ผ่ฏๅฅฝ็ๆฅๅธธ็ฎก็ไน ๆฏ่ฝๅคๆพ่ๆๅ็ๆใๅๅฐๅฏไฝ็จๅนถไฟ่ฟ้ฟๆๅฅๅบทใ็งๅญฆ็้ฅฎ้ฃ่ฐๆดใ้ๅบฆ่ฟๅจๅ้ซไพไปๆงๆฏ็กฎไฟGLP-1ๅ้ๆนๆกๆๅ็ๅ ณ้ฎใไปฅไธไธบGLP-1ๅ้ๆ้ด็ๅฎ็จๆฅๅธธ็ฎก็ๅปบ่ฎฎใ
ๅจGLP-1ๅ้ๆนๆกๆ้ด๏ผๅปบ่ฎฎๆฃ่ ้็จไฝ็ญ้ใๅ่กก่ฅๅ ป้ฅฎ้ฃ๏ผๅขๅ ไผ่ดจ่็ฝๅ่ฌ่ๆๅ ฅ๏ผๅๅฐ้ซ็ณใ้ซ่่ช้ฃ็ฉใๅฐคๅ ถๆฏๅจไฝฟ็จๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผๆ่ฏบๅ่พพๆ้ด๏ผๅปบ่ฎฎๅฐ้ๅค้ค๏ผ้ฟๅ ๆด้ฅฎๆด้ฃๅๆฒน่ ป้ฃ็ฉ๏ผไปฅ้ไฝๆถๅฟใ่่็ญๅฏไฝ็จๅ็็ใๅฆๆๆถๅไธ้๏ผ้ๅฝ่ฐๆด้ฅฎ้ฃ็ปๆๅฏๆๆพๆนๅไพไปๆงๅ็จ่ฏไฝ้ชใ
GLP-1่ฏ็ฉ่ฝ่ฝๆๆๆๅถ้ฃๆฌฒ๏ผไฝ็ปๅ่งๅพ่ฟๅจ๏ผๅฆๅฟซ่ตฐใๆธธๆณณใ็ไผฝ็ญๆๆฐง่ฟๅจ๏ผๆดๆๅฉไบๅ ้่่ชๆถ่๏ผๅทฉๅบไฝ้็ฎก็ๆๆใๅปบ่ฎฎๆฏๅจ่ณๅฐ่ฟ่ก150ๅ้ไธญ็ญๅผบๅบฆ่ฟๅจใๅๆถ๏ผไฟๆ่ฏๅฅฝไฝๆฏใๅ ่ถณ็ก็ ไธๅฟ็ๅฅๅบท๏ผๅฏน่ฏ็ฉ็ๆๅ่บซไฝๆขๅคไนๆ็งฏๆไฝ็จใ้ฟๆๅฅๅบท็ๆดปๆนๅผๆฏๅฎ็ฐ็จณๅฎใๅฏๆ็ปญๅ้็ไฟ้ใ
ไฝฟ็จๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผใๅธ็พๆ ผ้ฒ่ฝ็๏ผ่ฏบๅ่พพ๏ผ็ญGLP-1่ฏ็ฉๆถ๏ผๅปบ่ฎฎไธฅๆ ผๆ็ งๅป็ๆๅฏผ็จ่ฏ๏ผไธ้ๆๆดๆนๅ้ๆๅ่ฏใๅฆๅบ็ฐๅฏไฝ็จ๏ผๅบๅๆถไธๅป็ๆฒ้๏ผ่ทๅไธชๆงๅ่ฐๆดๅปบ่ฎฎใๅฎๆ้่ฎฟใ่ฎฐๅฝไฝ้ๅ้ฅฎ้ฃ่ฟๅจๆ ๅตๆๅฉไบๅๆถๅ็ฐ้ฎ้ขๅนถไผๅๆฒป็ๆนๆกใๅฎถไบบๅๆๅ็ๆฏๆไนๆๅฉไบๆๅไพไปๆงๅๅ้ๅจๅใ
ๅจ้ๆฉๅ่ฅๆนๆกๆถ๏ผๆฃ่ ๅธธๅธธไผๅฏนGLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใใๅธ็พๆ ผ้ฒ่ฝ็ใ่ฏบๅ่พพใ๏ผไธไผ ็ป่ฏ็ฉใไปฃ้คใๆๆฏ็ญๆนๆณ่ฟ่กๅฏนๆฏใไบ่งฃๅ็ฑปๆนๆก็ไผๅฟไธๅฑ้๏ผๆๅฉไบ็งๅญฆๅณ็ญๅนถๅน้ ไธชไบบ้ๆฑใไปฅไธๅฐ้ๅฏนไธป่ฆๅปๅญฆๅ้ๆๆฎต่ฟ่กๅฎข่งๅๆใ
GLP-1็ฑป่ฏ็ฉ้่ฟ่ฐ่่ ้ๆฟ็ด ใๆๅถ้ฃๆฌฒใๅปถ็ผ่ๆ็ฉบ๏ผๅฎ็ฐ็งๅญฆๅ้๏ผ่ไผ ็ปๅฃๆๅ่ฅ่ฏ๏ผๅฆ้ฃๆฌฒๆๅถๅใ่่ชๅธๆถๆๅถๅ็ญ๏ผๅค้่ฟๅไธๆบๅถๆไธญๆข็ฅ็ปๅ ดๅฅไฝ็จ่ตทๆใGLP-1็ฑป่ฏ็ฉๅฏไฝ็จ็ธๅฏนๆธฉๅไธๅฎๅ จๆง้ซ๏ผไธๅซ็ฒพ็ฅ็ฑปๆๅ๏ผไธๆๆ็พ๏ผๆด้ๅ้ฟๆๅปๅญฆ็็ฎกไธ่ง่ไฝฟ็จใ
ไปฃ้คๅ่้ฃไธป่ฆไพ่ต็ญ้้ๅถ๏ผ็ญๆๅฏ่งไฝ้ไธ้๏ผไฝๅฎนๆๅผๅ้ฅฅ้ฅฟๆใ่ฅๅ ปไธๅ่กกๅๅๅผน้ฃ้ฉใGLP-1็ฑป่ฏ็ฉๅฏ่ช็ถ่ฐ่้ฃๆฌฒ๏ผๅขๅผบ้ฅฑ่ นๆ๏ผไฝฟๆฃ่ ๆดๆๅๆๅ็้ฅฎ้ฃ๏ผไปๆ นๆฌไธๆนๅ้ฅฎ้ฃ็ปๆ๏ผๆๅฉไบ้ฟๆ็จณๅฎๅ้ๅนถ้ไฝๅค่็ใ
ๅ้ๆๆฏ๏ผๅฆ่่ข็ถๅ้คใ่ๆ่ทฏๆๆฏ๏ผ้็จไบ้ๅบฆ่ฅ่ๆๅๅนถไธฅ้ไปฃ่ฐข็พ็ ๆฃ่ ๏ผ่ฝ็ถๆๆฏๅ้ๆๆๆพ่๏ผไฝๅฑไบๆๅๆไฝ๏ผ้ไฝ้ขๅ้ฟๆ้่ฎฟ๏ผๅญๅจๆๆฏ้ฃ้ฉใGLP-1่ฏ็ฉไธบ้ๆๆฏใๅฏ้ๆงๆนๆก๏ผ้ๅ่ฝปไธญๅบฆ่ฅ่ๅๅธๆไปฅ่ฏ็ฉไธบไธปๅฏผ็ฎก็ไฝ้็็พคไฝใ้จๅ้ๅบฆ่ฅ่ๆฃ่ ไนๅฏๅจๆๆฏๅๅ่พ ๅฉไฝฟ็จGLP-1่ฏ็ฉไปฅๆๅ็ปผๅ็ๆใ
GLP-1่ฏ็ฉ๏ผๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใใ่ฏบๅ่พพ๏ผไผๅฟๅจไบๆบๅถ็งๅญฆใๅฎๅ จๆง้ซใไพไปๆงๅฅฝ๏ผๅนถๅฏ้ๅฏนไธชไบบไฝ่ดจ่ฟ่กไธชๆงๅๅ้่ฐๆดใๅฑ้ๅจไบ้จๅๆฃ่ ๅฏ่ฝๅบ็ฐ่่ ไธ้๏ผ้ๅๆ็จ่ฏไธ้่ฎฟ็ฎก็ใ่ฏ็ฉไปทๆ ผ็ธๅฏนไผ ็ปๆนๆณ่พ้ซ๏ผ้ๅจๅป็ๆๅฏผไธ็งๅญฆ้ๆฉๅนถๆ่กก็ปๆตๅ ็ด ใ
GLP-1็ฑป่ฏ็ฉ๏ผๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ่ฏไนๅ่ฝใ็ชๆฉไฝณใ่ฏบๅ่พพ๏ผๅฎๅ จๅ๏ผ
GLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใใๅธ็พๆ ผ้ฒ่ฝ็ใ่ฏบๅ่พพใ๏ผๅจๅป็ๆๅฏผไธๆปไฝๅฎๅ จๆง่พ้ซใๅธธ่งๅฏไฝ็จๅคไธบ่ฝปๅบฆๆถๅฟใ่่ใ่ นๆณป็ญ๏ผ้ๅธธ้็็จ่ฏๆถ้ดๅปถ้ฟ้ๆญฅๅ่ฝปใๅฆๅบ็ฐๆๆพไธ้๏ผๅบๅๆถ่็ณปๅป็่ฐๆดๅ้ๆๅค็ไธ่ฏๅๅบใ
GLP-1ๅ่ฅ่ฏ็ฉๅคไน ่ฝ่งๆ๏ผ
ๅคๆฐๆฃ่ ๅจ่ง่ไฝฟ็จๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผๆ่ฏบๅ่พพๅ๏ผ1-2ๅจๅ ๅณๅฏๆ่ง้ฃๆฌฒไธ้๏ผไฝ้้ๅธธๅจ4-8ๅจๅ ๅผๅงๆๆพไธ้ใๆ็ป็ๆๅ ไธชไฝไฝ่ดจใๅ้ๅไพไปๆงไธๅ่ๆๆๅทฎๅผใ้ฟๆๅๆๅนถ้ ๅ็งๅญฆ้ฅฎ้ฃใ่ฟๅจ๏ผๆๆๆดๅ ็ๆณใ
ไฝฟ็จGLP-1่ฏ็ฉๅไฝ้ไผๅๅผนๅ๏ผ
ๅฆๅ่ฏๅ้ฅฎ้ฃใ็ๆดปไน ๆฏๆช่ฝๆ็ปญๆนๅ๏ผไฝ้ๅฏ่ฝๅบ็ฐไธๅฎ็จๅบฆๅๅผนใ็งๅญฆ็ ็ฉถ่กจๆ๏ผๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝๅ่ฏบๅ่พพ็ญGLP-1่ฏ็ฉๆๅฉไบ้ฟๆๆนๅ้ฃๆฌฒๅ้ฅฎ้ฃ็ปๆ๏ผ่ฅๅจๅป็ๆๅฏผไธ้ๆญฅๅ่ฏๅนถ็ปดๆๅฅๅบท็ๆดปๆนๅผ๏ผๅคๆฐๆฃ่ ๅฏไฟๆๅ้ๆๆใ
็จGLP-1่ฏ็ฉ้่ฆ้ ๅ้ฅฎ้ฃๅ่ฟๅจๅ๏ผ
GLP-1็ฑป่ฏ็ฉ๏ผๅ ๆฌๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ่ฏไนๅ่ฝใ็ชๆฉไฝณใ่ฏบๅ่พพ๏ผ่ฝ่ฝๆๆๆๅถ้ฃๆฌฒ๏ผไฝๆไฝณ็ๆไป้้ ๅไฝ็ญ้้ฅฎ้ฃๅ่งๅพ่ฟๅจใ็งๅญฆ้ฅฎ้ฃ็ปๆไธ้ๅบฆ่ฟๅจไธไป ๅฏๅขๅผบ่ฏ็ฉๅ้ๆๆ๏ผ่ฟ่ฝ่ฟไธๆญฅๆนๅๆฐ้ไปฃ่ฐขๅๆดไฝๅฅๅบท็ถๅตใ
GLP-1่ฏ็ฉๅฏไปฅ็ฝไธ่ดญไนฐๅ๏ผ
ๅจๆฐๅ ๅก๏ผๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผๅ่ฏบๅ่พพ็ญGLP-1่ฏ็ฉๅๅฑไบๅคๆน่ฏ๏ผๅฟ ้กป็ฑๆณจๅๅป็ๅผๅ ทๅคๆนใไธฅ็ฆ้่ฟ็ฝ็ปใไปฃ่ดญๆ้ๆญฃ่งๆธ ้่ดญไนฐ๏ผไปฅๅ ๅบ็ฐๅ่ฏๆ็จ่ฏ้ฃ้ฉใๅปบ่ฎฎๅฐๆญฃ่งๅป็ๆบๆ้ข่ฏ๏ผ็ฑๅป็่ฏไผฐๅๆๅฏผ็งๅญฆๅ้ใ
GLP-1็ฑป่ฏ็ฉๅ่ฅๆฒป็่ดน็จๆฏๅคๅฐ๏ผ
ๅ้่ดน็จๆ นๆฎๆ้่ฏ็ฉ็ฑปๅ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใๆ่ฏบๅ่พพ๏ผใๅ้ๅ็็จ้ฟ็ญๆๆไธๅใๅปบ่ฎฎๆฃ่ ้ข่ฏๅ็ฑๅป็ๆ นๆฎไธชไฝ้ๆฑๅ้ข็ฎ๏ผๅฎๅถๆๅ้็็งๅญฆๅ้ๆนๆกใๅ ทไฝ่ดน็จ่ฏทๅจ่ฏข่ฏๆๅทฅไฝไบบๅ่ทๅๆๆฐไฟกๆฏใ
ๅญๅฆๆๅบไนณๆๅฅณๆงๅฏไปฅไฝฟ็จGLP-1่ฏ็ฉๅ๏ผ
GLP-1็ฑป่ฏ็ฉ๏ผๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ็ญ๏ผไธๅปบ่ฎฎๅญๅฆๆๅบไนณๆๅฅณๆงไฝฟ็จใๅฏนไบ่ฎกๅๆๅญๆๅคไบ็นๆฎ็็้ถๆฎต็ๆฃ่ ๏ผๅกๅฟ ๆๅๅๅป็่ฏดๆ๏ผ็ฑไธไธๅป็่ฏไผฐ้ฃ้ฉไธ็จ่ฏๅฎๅ จๆงใ
GLP-1่ฏ็ฉๅฏไปฅ้ฟๆไฝฟ็จๅ๏ผ
็ฎๅ็ ็ฉถๅไธดๅบ็ป้ชๆพ็คบ๏ผๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ็ญGLP-1่ฏ็ฉๅฏๅจๅป็ๆๅฏผไธไธญ้ฟๆไฝฟ็จ๏ผไธๅฎๅ จๆง่ฏๅฅฝใๆฏๅฆ้ฟๆ็จ่ฏ้ๆ นๆฎไธชไบบๅฅๅบท็ถๅตใๅ้็ฎๆ ๅๅป็ๅปบ่ฎฎ็ปผๅๅคๆญ๏ผ่ฟ็จไธญ้ๅฎๆ้่ฎฟใๅจๆ่ฏไผฐใ
ไธๅGLP-1่ฏ็ฉ๏ผๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผๅฆไฝ้ๆฉ๏ผ
่ฏ็ฉ้ๆฉๅบๆ นๆฎไธชไบบไฝ่ดจใ็ๆดปๆนๅผใๆณจๅฐๆๅฃๆๅๅฅฝๅๆขๅพ็จ่ฏๅฒ็ปผๅ่ฏไผฐใๆฏๅจๆณจๅฐๅ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใ๏ผ้ๅไพไปๆง้ซไธไธๆง้ๅ่ ๏ผๆฏๆฅๅฃๆๅ่ฏบๅ่พพ้ๅไธไพฟๆณจๅฐไบบ็พคใๆ็ปๆนๆกไปฅๅป็ไธไธๅปบ่ฎฎไธบๅใ
GLP-1็ฑป่ฏ็ฉไผๅฝฑๅ่ก็ณๅ๏ผ
GLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใใ่ฏไนๅ่ฝใ็ชๆฉไฝณใใ่ฏบๅ่พพ๏ผๅฏไฟ่ฟ่ฐๅฒ็ด ๅๆณใๆๅถ่ฐ้ซ่ก็ณ็ด ้ๆพ๏ผๆๅฉไบ็จณๅฎ่ก็ณๆฐดๅนณใๅฏนไบ้จๅไผดๆ็ณ่้ๅผๅธธๆ็ณๅฐฟ็ ้ฃ้ฉ็่ฅ่่ ๏ผGLP-1่ฏ็ฉไธไป ๆๅฉไบๅ้๏ผไนๅฏ่พ ๅฉๆนๅ่ก็ณๆงๅถใไฝไฝ่ก็ณ้ฃ้ฉ่พไฝ๏ผๅฆไธๅ ถไป้็ณ่ฏ็ฉ่ๅ็จ่ฏ้้ตๅปๅฑใ
ๆ็จGLP-1่ฏ็ฉๆ้ด่ฝๅฆไธๅ ถไปๆ ขๆง็ ่ฏ็ฉๅๆถไฝฟ็จ๏ผ
ๅคงๅคๆฐGLP-1่ฏ็ฉ๏ผๅ ๆฌๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ่ฏไนๅ่ฝใ็ชๆฉไฝณใ่ฏบๅ่พพ๏ผๅฏไธๅธธ่งๆ ขๆง็ ่ฏ็ฉ๏ผๅฆ้ๅ่ฏใ้่่ฏ๏ผๅๆถไฝฟ็จ๏ผไฝๅ ทไฝ็จ่ฏ็ปๅ้ๅป็่ฏไผฐใ้จๅ่ฏ็ฉ้ดๅญๅจ็ธไบไฝ็จ้ฃ้ฉ๏ผไฝฟ็จๅๅกๅฟ ไธปๅจๅๅป็ๅ็ฅๆๆๅจ็จ่ฏ็ฉใ
ๅ้็ฎๆ ่พพๆๅ่ฝๅฆๅ่ฏ๏ผๅฆไฝๅ่ฏ๏ผ
่พพๅฐ็ๆณไฝ้ๅ๏ผ้จๅๆฃ่ ๅฏๅจๅป็ๆๅฏผไธ้ๆญฅๅๅฐๆๅ็จGLP-1่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผใๅปบ่ฎฎๅพชๅบๆธ่ฟ๏ผๅฏๅ่งๅฏไฝ้ๅไปฃ่ฐขๅๅ๏ผ้ฟๅ ็ช็ถๅ่ฏๅฏผ่ดไฝ้ๅๅผนใ้ฟๆ็ปดๆๅฅๅบท้ฅฎ้ฃๅ็ๆดปไน ๆฏๆฏ้ฒๆญขๅค่็ๅ ณ้ฎใ
GLP-1่ฏ็ฉ้ๅๅชไบๅนด้พๆฎต๏ผ
GLP-1็ฑป่ฏ็ฉ๏ผๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ่ฏไนๅ่ฝใ็ชๆฉไฝณใ่ฏบๅ่พพ๏ผไธ่ฌๅปบ่ฎฎ็จไบ18-70ๅฒ็ๆๅนดไบบใๆชๆๅนดไบบไธ้ซ้พ่ไบบ็จ่ฏ้ไธฅๆ ผๅป็่ฏไผฐใๅญๅฆใๅบไนณๆๅฅณๆงๅ็นๆฎๆ ขๆง็ ๆฃ่ ไฝฟ็จๅๅกๅฟ ๆๅๅจ่ฏขๅป็ใ
GLP-1่ฏ็ฉๅ่ฐๅฒ็ด ๆไฝๅบๅซ๏ผ
GLP-1่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผไธป่ฆ้่ฟ่ฐ่่ ้ๆฟ็ด ๏ผๆๅถ้ฃๆฌฒๅนถไฟ่ฟ่ฐๅฒ็ด ๅๆณ๏ผ้็จไบๅ้ๅๆนๅไปฃ่ฐขใ่่ฐๅฒ็ด ไธบ็ดๆฅ้็ณ่ฏ๏ผๅค็จไบ็ณๅฐฟ็ ๆฒป็๏ผไฝ็จๆบๅถๅ้็จไบบ็พคไธๅใไธค่ ไธๅฏ็ธไบๆฟไปฃใ
ๅฏไปฅ่ทจๅฝๆบๅธฆGLP-1่ฏ็ฉๅ๏ผๆไฝๆณจๆไบ้กน๏ผ
ๅคง้จๅGLP-1่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผๅฏ้่บซๆบๅธฆๅบๅ ฅๅข๏ผไฝ้้่บซๆบๅธฆๅป็ๅคๆนๅๅๅ ่ฃ ่ฏๅใ้จๅๅฝๅฎถๅฏน่ฏๅๆบๅธฆๆ็นๆฎ่งๅฎ๏ผๅปบ่ฎฎๆๅไบ่งฃ็ฎ็ๅฐๆฟ็ญ๏ผ้ฟๅ ๅ ่ฏๅๆบๅธฆไธๅฝๅฝฑๅ่ก็จใ
GLP-1่ฏ็ฉ่ฝๅฆๆนๅ่ฅ่็ธๅ ณ็ไธ้ซ๏ผ้ซ่ก็ณใ้ซ่กๅใ้ซ่ก่๏ผ๏ผ
ๅฝ้ ไธดๅบ็ ็ฉถๆพ็คบ๏ผGLP-1็ฑป่ฏ็ฉ๏ผๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผๅฏๅธฎๅฉ้จๅๆฃ่ ๆนๅ่ก็ณใ่กๅๅ่ก่็ญไปฃ่ฐขๆๆ ๏ผ้ไฝไปฃ่ฐข็ปผๅๅพ้ฃ้ฉใไฝ่ฏ็ฉๅ้ไธๅบๆฟไปฃๅๆๆ ขๆง็ ๆฒป็ๆนๆก๏ผๅ ทไฝ็ฎก็ๆนๆก้ไธๅป็ๅๅๅถๅฎใ
GLP-1่ฏ็ฉๅ่ฅๆฏๅฆไผๅบ็ฐ่่ฏๆง๏ผ
็ฎๅ็ ็ฉถๆชๅ็ฐGLP-1็ฑป่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใๅฅฅ่ตๆฎใ็ปดๆ ผ็ปดใ่ฏไนๅ่ฝใ็ชๆฉไฝณใ่ฏบๅ่พพ๏ผๅญๅจๆๆพ่่ฏๆงใ้จๅๆฃ่ ไฝ้ไธ้้ๅบฆ้ๆฒป็ๆถ้ดๅปถ้ฟ่ๆพ็ผ๏ผๅฑๆญฃๅธธ็็่ฐ่ใ็งๅญฆ็จ่ฏใ้ ๅ็ๆดปๆนๅผ็ฎก็๏ผๆๅฉไบ้ฟๆไฟๆ็ๆใ
้ฆๆฌกๆณจๅฐๆๆ็จGLP-1่ฏ็ฉ้ๆณจๆไปไน๏ผ
ๅๆฌกไฝฟ็จGLP-1่ฏ็ฉ๏ผๅฆๅธ็พๆ ผ้ฒ่ฝใ่ฏไนๅ่ฝใ่ฏบๅ่พพ๏ผๅปบ่ฎฎๅจๅป็ๆๅฏผไธ่ฟ่ก๏ผๆณจๆ่งๅฏๆๆ ๆถๅฟใ่่็ญๅธธ่งๅฏไฝ็จใๅบไธฅๆ ผๆ็ งๅป็ๅปบ่ฎฎ็ๅ้็จ่ฏ๏ผไธ้ๆๅขๅ ๆๅๅฐๅ้ใๅฆๆๆๆพไธ้๏ผๅๆถไธๅป็ๆฒ้่ฐๆดๆนๆกใ
GLP-1่ฏ็ฉ้ๅไบๆดฒไบบไฝ่ดจๅ๏ผ
ๅธ็พๆ ผ้ฒ่ฝ๏ผๅฅฅ่ตๆฎใ็ปดๆ ผ็ปด๏ผใ่ฏไนๅ่ฝ๏ผ็ชๆฉไฝณ๏ผใ่ฏบๅ่พพ็ญGLP-1่ฏ็ฉๅจไบๆดฒไบบ็พคไธญๅๆ ทๅ ทๆ่ฏๅฅฝ็ๅ้ๅไปฃ่ฐขๆนๅๆๆใไธดๅบ็ ็ฉถ่กจๆ๏ผไบๆดฒ่ฅ่ๅไปฃ่ฐขๅผๅธธๆฃ่ ๅฏนGLP-1่ฏ็ฉๅๅบ่ฏๅฅฝ๏ผๅ ทไฝๆนๆกๅปบ่ฎฎ็ปๅไธชไบบไฝ่ดจไธๅป็ๅปบ่ฎฎๅถๅฎใ
ๅฆ้้ข็บฆๅป็ๅจ่ฏขใไบ่งฃGLP-1ๅ้ๆนๆก๏ผๆฌข่ฟ้่ฟไปฅไธๆนๅผไธๆไปฌ่็ณป๏ผ
่ฏๆๅฐๅ๏ผ
่ฅไธๆถ้ด๏ผ
ๆไปฌๆฏๆไธญ่ฑๆๆๅก๏ผไธฅๆ ผไพ็ งๆฐๅ ๅกๅปๅญฆ่ง่๏ผๆๆGLP-1ๅ้ๆนๆกๅ็ฑๆณจๅๅป็ไบฒ่ช่ฏไผฐไธ็ฎก็ใๅฆๆไปปไฝ็้ฎ๏ผๆฌข่ฟ้ๆถ่็ณปๆไปฌ๏ผๆไปฌๅฐไธบๆจๆไพไธไธใๅฎๅ จใ้ซๆ็ๅปๅญฆๅ้ๆๅกใ
Persistent or severe acne often requires more than just topical creams or over-the-counter solutions. For many individuals in Singapore, prescription oral acne medication offers a more effective way to address stubborn, moderate, or cystic acne that does not respond to standard skincare treatments.
At Edwin Lim Medical Aesthetic Clinic, our doctor-led approach ensures every oral acne treatment plan is carefully tailored to your skin type, acne severity, and medical history.
We offer a full range of prescription oral medicationsโincluding antibiotics, spironolactone for hormonal acne, and isotretinoinโto target the underlying causes of acne such as inflammation, bacteria, and hormonal imbalances.
By starting oral acne medication under the supervision of an experienced aesthetic doctor, patients benefit from expert assessment, ongoing monitoring, and evidence-based treatment adjustments.
If you are seeking prescription oral medication for acne in Singapore, our clinic provides comprehensive, doctor-guided care to help you achieve clearer, healthier skin.
While many cases of mild acne can be managed with topical creams or gels, oral acne medication is often required for individuals with more severe, persistent, or cystic acne.
Oral medications are designed to work from within, addressing the underlying causes of acne that topical treatments may not fully control.
Oral prescription medications are especially effective for:
By targeting inflammation, bacteria, and hormonal factors, prescription oral acne medications can provide more consistent and longer-lasting results. For patients who have struggled with acne despite using topical therapies, starting oral treatment under medical supervision offers a safe and scientifically proven pathway to clearer skin.
At Edwin Lim Medical Aesthetic Clinic, every oral acne medication plan is customised following a comprehensive consultation, ensuring the highest standard of safety and efficacy for each patient.
For patients with persistent, moderate, or severe acne, oral medications are often the most effective treatment option. At our clinic, all oral acne therapies are prescribed and closely monitored by our doctor to ensure optimal safety and results.
The main categories of prescription oral acne medications include oral antibiotics, spironolactone for hormonal acne, and isotretinoin.
Oral antibiotics are a cornerstone in the treatment of moderate to severe inflammatory acne, especially when topical treatments alone are insufficient.
These medications work by reducing the levels of acne-causing bacteria (Cutibacterium acnes) within the skin and by decreasing inflammation, which in turn helps to clear existing breakouts and prevent new ones from forming.
Types of Oral Antibiotics Commonly Prescribed in Singapore:
A typical course ranges from 3 to 6 months. Some patients may experience mild side effects, such as stomach discomfort or photosensitivity, so it is important to take the medication with food and use sun protection.
How Long Are Oral Antibiotics Taken for Acne?
Oral antibiotics are typically prescribed for a finite periodโusually a few weeks to several monthsโuntil active inflammation has significantly improved. The aim is to use the lowest effective dose for the shortest time possible to minimise the risk of developing antibiotic resistance.
Side Effects and Precautions:
Most patients tolerate oral antibiotics well, but possible side effects include mild stomach upset, diarrhoea, or increased sensitivity to sunlight (especially with doxycycline). It is essential to follow your doctorโs instructions regarding dosage, food interactions, and sun protection.
Combining Oral Antibiotics with Other Acne Treatments:
For enhanced effectiveness and to prevent antibiotic resistance, oral antibiotics are almost always used in combination with topical acne medications, such as retinoids or benzoyl peroxide. This multimodal approach allows for comprehensive acne control while reducing the overall duration of antibiotic use.
Regular Review and Follow-Up:
At our clinic, patients receiving oral antibiotics are reviewed regularly to assess progress, adjust treatment if necessary, and monitor for any potential side effects.
Spironolactone is an oral medication that specifically targets acne caused or worsened by hormonal imbalances, making it especially effective for women who experience persistent adult acne, jawline or lower face breakouts, or acne that flares with the menstrual cycle.
How Does Spironolactone Work for Acne?
Spironolactone acts as an anti-androgen, blocking the effects of male hormones (androgens) that can trigger increased oil production in the skin. By reducing sebum (oil) production, spironolactone helps prevent clogged pores and reduces the frequency and severity of breakouts, particularly in areas such as the jawline, chin, and lower cheeks.
Who is Suitable for Spironolactone Therapy?
Spironolactone is suitable for adult women who:
This medication is not typically prescribed for men or for adolescent girls who have not reached puberty.
What to Expect During Spironolactone Treatment:
Improvements are usually noticeable after 2โ3 months of consistent use. Dosing is personalised based on your medical history and acne severity.
Common side effects may include mild diuresis (increased urination), menstrual cycle changes, or breast tenderness, but most women tolerate the medication well. Regular blood pressure and electrolyte monitoring may be recommended to ensure ongoing safety.
Advantages of Spironolactone for Hormonal Acne:
At our clinic, we provide thorough evaluation and monitoring for every patient on spironolactone to ensure effective and safe results.
Oral isotretinoinโcommonly known by the brand name Accutaneโis considered the gold standard for treating severe, cystic, or treatment-resistant acne.
It is a vitamin A derivative (retinoid) that targets all major contributors to acne: excess oil production, abnormal skin cell turnover, inflammation, and bacterial growth.
How Does Isotretinoin Work for Acne?
Isotretinoin dramatically reduces the size and activity of oil glands, prevents clogged pores, and significantly decreases inflammation. This results in substantial and often long-lasting clearance of even the most severe acne cases.
Who Should Consider Isotretinoin?
What is the Typical Course of Isotretinoin Treatment?
A typical course of isotretinoin lasts at least 6โ12 months, with dosing tailored to each patientโs weight and severity of acne. Most patients see major improvement within the first few months, and many experience long-term remission after completing therapy.
Monitoring and Safety During Isotretinoin Therapy:
Due to its potency, isotretinoin is only prescribed under close medical supervision. Patients undergo regular blood tests to monitor liver function, cholesterol, and other health parameters. Women of childbearing age require strict birth control measures during treatment due to the risk of birth defects.
Common Side Effects:
Temporary side effects can include dry lips, dry skin, and increased sun sensitivity. Rare side effects may include changes in mood, muscle aches, or laboratory abnormalities, all of which are closely monitored during follow-up visits.
Why Choose Isotretinoin for Severe Acne?
Isotretinoin remains the most effective oral medication for achieving long-term, and sometimes permanent, acne clearance in suitable candidates. At our clinic, patients considering isotretinoin receive comprehensive counselling, personalised dosing, and ongoing monitoring for the safest and most successful treatment outcomes.
Choosing the right oral acne medication requires careful consideration of each patientโs unique skin condition, medical history, and lifestyle factors. At our clinic, every prescription begins with a comprehensive assessment by Dr Edwin Lim, ensuring that your acne treatment plan is both effective and safe.
Key factors your doctor will consider include:
Personalised Acne Treatment Plans
Based on your initial consultation and any necessary laboratory tests, our doctor will recommend the most appropriate oral medication or combination therapy.
Throughout your treatment journey, regular reviews and monitoring ensure that your medication remains effective, side effects are minimised, and your skin continues to improve.
By following a doctor-guided, evidence-based approach, you can achieve clearer skin with reduced risk of complications and long-term side effects.
Your treatment journey begins with a comprehensive skin evaluation and a review of your medical history by our doctor. For certain medications, such as isotretinoin, baseline blood tests may be recommended to ensure suitability and safety.
Based on your individual needs, our doctor will prescribe the most appropriate oral acne medication and explain how to take it. You will receive detailed instructions regarding dosing, timing, potential interactions, and lifestyle considerations such as sun protection or dietary advice.
Most patients begin to notice improvement within 4 to 8 weeks of starting oral acne medication, though optimal results may require several months of consistent use. Adherence to the prescribed regimen is key for best outcomes and to prevent relapse.
Ongoing follow-up appointments are essential to monitor your skinโs progress, detect any side effects early, and adjust medication dosages if needed. For medications such as isotretinoin or spironolactone, periodic blood tests or health checks may be performed for added safety.
While oral acne medications are generally well tolerated, side effects such as mild gastrointestinal discomfort, dry skin, or headaches may occasionally occur. Our clinic provides ongoing support and guidance to address any side effects promptly and safely.
After your acne is controlled, our doctor will develop a maintenance plan tailored to your needs. This may include slowly reducing medication, transitioning to topical therapies, or introducing lifestyle strategies to keep your skin clear in the long term.
Not everyone with acne requires oral medication, but for certain individuals, prescription oral therapies provide the best chance of achieving clear and healthy skin. At our clinic, suitability for oral acne medication is determined through a detailed consultation and skin assessment by our doctor.
Oral acne medications are most appropriate for:
Who may not be suitable for oral acne medication?
Oral therapies are generally not recommended for:
At our clinic, your doctor will carefully review your acne severity, medical history, and treatment goals to determine if oral medication is appropriate. If so, a personalised prescription and follow-up plan will be provided to ensure the best results with maximum safety.
While oral acne medications are highly effective for moderate to severe acne, they require careful prescription and ongoing monitoring to minimise potential risks and side effects. At our clinic, patient safety is always the top priority.
Every oral acne treatment plan is customised with strict safety protocols and regular follow-up to ensure you receive the benefits of therapy with minimal complications.
Common Risks and Side Effects:
Safety Precautions and Monitoring:
By following a doctor-led, evidence-based protocol, the risks of oral acne medication can be minimised, and the benefits maximised. Our clinic is committed to ensuring that your treatment is safe, effective, and individually tailored at every step.
For many individuals, combining prescription oral acne medication with other doctor-recommended treatments provides faster, more complete, and longer-lasting results.
At our clinic, we take a holistic, personalised approachโoften integrating oral therapies with advanced acne medical facials, proprietary medical-grade skincare, and the latest laser technologies.
Benefits of Combination Acne Therapy:
Examples of Our Doctor-Led Combination Treatments:
Ongoing Doctor Supervision:
At every stage, your combination acne treatment plan is supervised by our doctor to ensure safety, optimal progress, and timely adjustments as your skin responds. Regular follow-up appointments provide a chance to review your results and fine-tune your regimen for the best possible outcome.
By integrating oral medication with advanced acne facials, targeted laser treatments, and doctor-developed skincare, our clinic offers a comprehensive, results-driven approach for acne treatment in Singapore.
What Is the Most Effective Oral Medication for Acne?
The most effective oral medication for acne depends on the severity, type of acne, and individual patient factors. Common options prescribed by doctors in Singapore include oral antibiotics (such as doxycycline, minocycline, or azithromycin), spironolactone for hormonal acne in women, and oral isotretinoin for severe or cystic acne. A doctor will recommend the best option based on your skinโs needs and medical history.
How Long Do I Need to Take Oral Acne Medication?
Treatment duration varies depending on the chosen medication and the severity of your acne. Oral antibiotics are typically prescribed for 3 to 6 months, while spironolactone may be continued long term if well tolerated. Oral isotretinoin is usually prescribed as a single course lasting 4 to 8 months. Your doctor will monitor your progress and advise when it is appropriate to stop or adjust your medication.
Are Oral Acne Medications Safe?
When prescribed and monitored by an experienced doctor, oral acne medications are generally safe. However, all medications can have potential side effects, such as stomach upset with antibiotics, menstrual changes with spironolactone, or dryness and sun sensitivity with isotretinoin. Regular follow-up and laboratory monitoring help to ensure safety throughout your treatment.
Do I Need Blood Tests When Taking Oral Acne Medication?
Certain oral acne medications, especially isotretinoin and spironolactone, require periodic blood tests to monitor liver function, cholesterol, kidney function, and electrolytes. These safety checks are a standard part of doctor-led acne care in Singapore and help to identify any rare complications early.
Can I Combine Oral Acne Medication With Other Treatments?
Yes. In many cases, combining oral acne medication with professional skincare, medical facials, or acne laser treatments leads to faster and more complete results. Our clinic offers integrated combination therapy to maximise effectiveness and maintain skin health.
Is Oral Acne Medication Suitable for Teenagers?
Many oral acne medications are suitable for teenagers, especially those with moderate to severe acne that does not respond to topical treatments. Some medications, such as spironolactone, are typically reserved for adult women. A consultation with our doctor will help determine the most appropriate and safe option for each patient.
Will My Acne Return After Stopping Oral Medication?
While many patients experience long-term improvement after a course of oral medication, acne can sometimes recur. Your doctor may recommend a maintenance plan, which could include transitioning to topical treatments, medical facials, or regular use of doctor-developed skincare to maintain clear skin and prevent relapse.
Do I Need a Doctorโs Prescription for Oral Acne Medication in Singapore?
Yes. All effective oral acne medications, including antibiotics, spironolactone, and isotretinoin, require a doctorโs prescription in Singapore. It is important to undergo a thorough medical assessment before starting any oral medication to ensure it is safe and appropriate for your skin type and health status.
How Soon Will I See Results With Oral Acne Medication?
Most patients begin to see improvements within 4 to 8 weeks after starting oral acne medication. The timeline varies based on the severity of acne, type of medication, and individual response. Maximum results are usually achieved after several months of consistent, doctor-supervised treatment.
How Do I Start Oral Acne Medication Treatment at Your Clinic?
To begin treatment, simply book a consultation with our clinic. During your visit, our doctor will assess your skin, discuss your goals, and recommend a personalised oral acne medication plan. Ongoing support and follow-up appointments are provided throughout your treatment journey for optimal safety and results.
Are There Any Dietary Restrictions While Taking Oral Acne Medication?
Most oral acne medications do not require major dietary restrictions, but some, such as doxycycline, are best taken with food to reduce stomach upset. Isotretinoin should be taken with a meal containing some fat for optimal absorption. It is also advisable to avoid excessive sun exposure and alcohol while on certain medications. Your doctor will provide detailed guidance based on your specific prescription.
Can Oral Acne Medication Help With Acne Scars?
Oral acne medications are effective in controlling active breakouts and reducing inflammation, which helps prevent new acne scars from forming. However, they do not treat existing acne scars. For scar improvement, your doctor may recommend combination therapy with medical facials, chemical peels, or laser treatments such as Pro Yellow acne laser.
What Should I Do If I Experience Side Effects From My Oral Acne Medication?
If you notice any side effectsโsuch as stomach upset, headaches, mood changes, skin dryness, or rashesโcontact our clinic promptly. Our doctor will assess the situation and may adjust your dosage, recommend supportive measures, or switch medications if necessary. Regular follow-up appointments are essential for early detection and management of side effects.
Can I Take Oral Acne Medication If I Am Planning to Get Pregnant?
Certain oral acne medications, especially isotretinoin, are strictly contraindicated during pregnancy due to the risk of birth defects. If you are planning to conceive, please inform your doctor before starting or continuing any oral acne medication. Our clinic will provide alternative acne management strategies and ensure your safety throughout the process.
How Is Hormonal Acne Treated With Oral Medication?
Hormonal acne, commonly seen in adult women and characterised by jawline, chin, or lower face breakouts, is often managed with oral medications such as spironolactone. This medication works by blocking androgen hormones that increase oil production and trigger acne. Your doctor will determine if hormonal therapy is suitable for your needs.
How Much Does Oral Acne Medication Cost in Singapore?
The cost of oral acne medication in Singapore varies based on the type of medication, treatment duration, and any required monitoring or blood tests. During your consultation, our clinic will provide a transparent breakdown of treatment fees, medication costs, and any follow-up appointments.
Can I Stop Oral Acne Medication Once My Skin Clears?
It is important not to discontinue oral acne medication abruptly, even if your skin looks clear. Stopping treatment too soon can lead to relapse. Your doctor will guide you on how to safely taper or stop your medication and recommend maintenance options to keep your skin clear in the long term.
Do Oral Acne Medications Interact With Other Medications or Supplements?
Some oral acne medications may interact with other prescription drugs, over-the-counter medications, or supplements. Be sure to inform your doctor of all products you are taking during your consultation. Our clinic will assess any potential interactions and recommend a safe, coordinated treatment plan.
Is Follow-Up Required After Completing Oral Acne Medication?
Yes, follow-up appointments are recommended even after completing a course of oral acne medication. This allows your doctor to monitor for relapse, manage any lingering side effects, and discuss long-term skin care strategies for maintaining results.
Can Men Take Spironolactone for Acne?
Spironolactone is primarily prescribed for women with hormonal acne. It is generally not recommended for men due to the risk of hormonal side effects such as breast enlargement or decreased libido. Alternative oral medications or topical treatments are available for male patients.
How Do I Know If I Need Oral Acne Medication?
If you have persistent, moderate, or severe acne that does not improve with topical products, or if you experience deep, painful cysts or frequent relapses, you may benefit from oral acne medication. A consultation with our doctor will provide a comprehensive evaluation and personalised treatment plan.
Are you looking for a reputable weight loss clinic in Singapore offering doctor-led, medically supervised weight loss programs?
Our clinic specialises in providing safe and effective weight management solutions tailored to each patientโs unique needs. Led by Dr Edwin Lim, an experienced weight loss doctor, we combine the latest medical treatments, prescription weight loss medications, and personalised support to help you achieve and maintain healthy, long-term results.
Whether you are seeking a structured weight loss program or expert guidance from a medical professional, our clinic is committed to supporting your weight loss journey at every step.
Choosing a medical weight loss clinic in Singapore ensures your weight management journey is safe, effective, and guided by an experienced weight loss doctor. With medical expertise and evidence-based protocols, you can achieve long-term, sustainable results under professional supervision.
A doctor-led weight loss clinic offers comprehensive care beyond what commercial or self-guided programs provide. Each patient receives:
Medical supervision ensures that all aspects of your weight loss programโfrom medication choice to monitoringโprioritise patient safety. Potential risks, side effects, and underlying health issues are promptly addressed, leading to better outcomes and reduced complications.
A key advantage of a medical weight loss clinic is the focus on long-term success. Your weight loss doctor will help you develop sustainable lifestyle habits and provide continued follow-up care to prevent weight regain and support your overall health.
When choosing a weight loss clinic in Singapore, it is essential to have confidence in the qualifications and experience of your weight loss doctor. At our clinic, every patient benefits from the guidance and supervision of Dr Edwin Lim, a highly qualified and experienced medical professional in weight management.
Dr Edwin Lim is dedicated to helping patients achieve their weight loss goals safely and effectively. With years of experience in medical aesthetics and weight management, he provides evidence-based recommendations and personalised care tailored to each individual.
Every patientโs weight loss journey is unique. Dr Lim works closely with you to understand your health background, lifestyle, and goals. This allows for the creation of a customised plan that prioritises your safety, well-being, and long-term success.
Throughout your weight loss program, Dr Lim provides continuous monitoring, follow-up consultations, and ongoing advice. This medical supervision ensures that your progress is closely tracked and any necessary adjustments are made for the best possible outcome.
Our clinicโs personalised medical weight loss program in Singapore is designed to help you achieve safe, sustainable, and long-term weight management under the care of an experienced weight loss doctor. Each program is tailored to your individual health profile, lifestyle, and goals for optimal results.
Your journey begins with a thorough medical evaluation, including detailed health screening, physical examination, and relevant laboratory tests. This assessment helps identify any underlying conditions that may affect your weight and determines the safest and most effective approach for your program.
Based on your assessment, your weight loss doctor develops a personalised plan that may include prescription weight loss medications, nutritional counselling, and lifestyle recommendations. Every aspect of your treatment is tailored to your unique needs, maximising both safety and effectiveness.
Ongoing monitoring is essential for achieving long-term success. We schedule regular follow-up consultations to review your progress, address any challenges, and adjust your treatment plan as needed. This continuous support ensures you stay on track toward your weight loss goals.
Our approach emphasises healthy lifestyle habits, including balanced nutrition, physical activity, and behavioural strategies. By supporting these changes alongside medical treatments, we help you maintain your results and promote lifelong health.
During your first visit to our weight loss clinic in Singapore, you will receive a comprehensive medical assessment and have the opportunity to discuss your weight management goals with our experienced weight loss doctor. This initial consultation is a crucial step in creating a safe, effective, and personalised program.
Your consultation begins with a thorough review of your medical history, current health status, and previous weight loss attempts. This may include physical examination and, if necessary, laboratory tests to assess metabolic health and identify any underlying conditions.
Your weight loss doctor will work with you to set achievable, medically appropriate weight loss goals. Together, you will discuss your expectations, desired outcomes, and any concerns you may have about the process.
Based on your assessment and goals, a customised weight loss plan will be developed for you. This plan may include prescription medications, nutritional advice, physical activity recommendations, and a follow-up schedule for ongoing monitoring and support.
You will receive detailed information about your proposed weight loss program, including the benefits, potential risks, and any medications that may be prescribed. All questions and concerns will be addressed to ensure you feel informed and confident before starting treatment.
Our medical weight loss clinic in Singapore offers a full range of clinically proven prescription treatments, all tailored to your unique needs and medical profile. These advanced medications are used under the supervision of an experienced weight loss doctor for optimal safety and results.
Our clinic provides once-weekly injectable weight loss medications that belong to the GLP-1 receptor agonist class.
These treatments, containing active ingredients such as semaglutide, are well known for their effectiveness in reducing appetite, improving satiety, and supporting steady weight reduction.
They are available in a variety of dosing strengths and are widely used for long-term weight management in Singapore and globally.
For patients seeking the latest breakthroughs in medical weight loss, we offer a dual-action injectable that combines both GLP-1 and GIP receptor agonist activity.
This medication, featuring tirzepatide as its active ingredient, delivers superior appetite suppression and metabolic support. It is especially effective for individuals who have struggled with weight loss using conventional methods or single-hormone therapies.
Some patients may prefer a daily oral approach to weight loss. Our clinic prescribes an oral GLP-1 medication containing semaglutide, designed to help control hunger, improve satiety, and promote gradual, sustainable weight loss.
This tablet-based option is ideal for those who are not suitable for injections or who prefer the convenience of oral medication.
All prescription weight loss treatments at our clinic are provided only after an in-depth assessment and consultation with our weight loss doctor.
Suitability is determined based on your BMI, overall health, and individual weight loss goals. Medication selection, dose titration, and side effect management are closely monitored at every stage to ensure optimal safety and effectiveness.
Regular follow-up appointments are scheduled to review progress, adjust treatment as needed, and provide personalised support throughout your program.
Medical weight loss programs at our clinic in Singapore are designed for individuals who require a structured, medically supervised approach to achieve safe and sustainable weight reduction.
Not everyone is a candidate for prescription weight loss medications, so a thorough medical assessment is essential to determine eligibility and ensure safety.
Before starting any weight loss medication, a comprehensive medical assessment is performed. This includes a review of your medical history, evaluation of current health status, and relevant laboratory tests.
The goal is to identify any underlying conditions and determine the safest, most appropriate treatment for your needs.
Medical weight loss medications are not suitable for everyone. They may not be appropriate for:
Our experienced weight loss doctor will advise you on the most suitable options based on your health profile, goals, and preferences. If prescription medications are not recommended, alternative weight management strategies will be discussed to support your journey.
Selecting the right weight loss clinic is a crucial step in achieving safe, effective, and lasting results. With many options available in Singapore, it is important to choose a clinic that offers doctor-led, medically supervised programs, a strong track record, and comprehensive patient support.
Our clinic is led by Dr Edwin Lim, an experienced weight loss doctor who provides individualised care for every patient. We offer evidence-based medical weight loss treatments, including advanced prescription medications and personalised programs tailored to each patientโs health profile and goals.
Unlike commercial weight loss centres, our clinic provides medical oversight at every stage of your journey. Regular consultations, progress reviews, and direct access to your weight loss doctor ensure you receive the highest level of support and care throughout your program.
Patient safety is our top priority. All treatments are prescribed only after comprehensive assessment and are closely monitored with regular follow-up appointments. Our approach focuses on sustainable results, healthy lifestyle changes, and ongoing education to help patients maintain their achievements long-term.
Our weight loss clinic in Singapore offers convenient locations and flexible appointment scheduling. We provide clear information, ongoing education, and a supportive environment to make your weight management journey as smooth and successful as possible.
Why Should I Choose a Medical Weight Loss Clinic Instead of a Commercial Program?
A medical weight loss clinic is led by a qualified doctor, offers evidence-based prescription treatments (such as Ozempic, Wegovy, Mounjaro, or Rybelsus), and provides ongoing medical supervision. This approach ensures your safety and the highest chance of long-term success.
What Happens During My First Visit With a Weight Loss Doctor?
At your first consultation, the weight loss doctor will review your medical history, discuss your goals, and perform a thorough assessment. You may be offered prescription options like Ozempic, Wegovy, Mounjaro, or Rybelsus if appropriate, along with a personalised weight loss program.
Am I Suitable for a Doctor-Led Weight Loss Program?
Suitability depends on your BMI, health background, and prior weight loss efforts. Your doctor will determine if prescription medications such as Ozempic, Wegovy, Mounjaro, or Rybelsus are safe and appropriate, or if alternative approaches may be better for you.
What Results Can I Expect From a Medically Supervised Program?
Most patients see steady, sustainable weight loss when following a medically supervised program that combines prescription medicationsโsuch as Ozempic, Wegovy, Mounjaro, or Rybelsusโwith healthy lifestyle changes. Progress is monitored to ensure safety and maximise results.
What Are the Side Effects of Prescription Weight Loss Medications?
Medications like Ozempic, Wegovy, Mounjaro, and Rybelsus may cause side effects such as nausea, digestive discomfort, or appetite changes. Most side effects are mild and temporary. Your doctor will provide advice on minimising side effects and adjust your plan if needed.
Can I Switch Between Different Prescription Weight Loss Medications?
Switching between medications may be possible depending on your needs and response to treatment. Options such as Ozempic, Wegovy, Mounjaro, and Rybelsus can be discussed with your doctor to ensure the most effective and suitable plan for you.
Do I Still Need to Change My Diet or Exercise While on These Medications?
Yes, for best results, a medical weight loss program always combines prescription medication (such as Ozempic, Wegovy, Mounjaro, or Rybelsus) with healthy eating and regular activity. Your program will include guidance on nutrition and exercise, tailored by your doctor.
How Do I Start a Medical Weight Loss Program in Singapore?
To begin, book a consultation at our clinic. Our weight loss doctor will assess your health, recommend the best program for you, and discuss prescription options like Ozempic, Wegovy, Mounjaro, or Rybelsus if they are suitable for your goals.
How Is a Medical Weight Loss Program Different From Standard Dieting?
A medical weight loss program at our clinic is overseen by a doctor and based on scientific principles. Unlike commercial diets or self-directed plans, our programs include medical assessment, prescription medications such as Ozempic, Wegovy, Mounjaro, or Rybelsus where appropriate, and continuous professional monitoring to ensure both safety and effectiveness.
Are Prescription Weight Loss Medications Available Without a Doctorโs Consultation in Singapore?
No, prescription medications like Ozempic, Wegovy, Mounjaro, and Rybelsus can only be provided by a licensed doctor after a thorough consultation and assessment. Medical supervision is essential to ensure the right medication, correct dosage, and safe use.
How Often Do I Need to See the Doctor During My Weight Loss Program?
Regular follow-up visits are important for safe and effective progress. Your weight loss doctor will typically schedule reviews every 4 to 8 weeks to monitor results, adjust medication (such as Ozempic, Wegovy, Mounjaro, or Rybelsus), and provide ongoing support as your program progresses.
Can Medical Weight Loss Programs Help With Weight-Related Health Conditions?
Yes, medical weight loss programs supervised by a doctor can help improve conditions such as type 2 diabetes, high blood pressure, and high cholesterol. Medications like Ozempic, Wegovy, and Mounjaro not only support weight loss but may also provide added health benefits for metabolic conditions.
Is It Possible to Regain Weight After Stopping Prescription Medications?
There is a risk of regaining weight after stopping medications such as Ozempic, Wegovy, Mounjaro, or Rybelsus if healthy habits are not maintained. Our clinic places strong emphasis on long-term lifestyle change and ongoing support to help you sustain results even after medication is discontinued.
Are There Age Limits for Joining a Medical Weight Loss Program?
Medical weight loss programs are generally recommended for adults aged 18 and above. Suitability for medications like Ozempic, Wegovy, Mounjaro, or Rybelsus will depend on your health assessment and the doctorโs recommendation.
Can I Use a Medical Weight Loss Program if I Have Other Medical Conditions?
Many patients with co-existing medical conditions can safely participate in a medical weight loss program, provided they are properly assessed by a doctor. Your doctor will evaluate your health history and consider potential interactions with medications such as Ozempic, Wegovy, Mounjaro, or Rybelsus.
How Do I Maintain My Results After Completing a Medical Weight Loss Program?
Our clinicโs approach to weight management emphasises sustainable habits and regular medical follow-up. After completing a program involving medications like Ozempic, Wegovy, Mounjaro, or Rybelsus, your doctor will advise on nutrition, physical activity, and ongoing check-ups to help you maintain your results long-term.
Copyrights 2026 by Edwin Lim Medical Aesthetic Clinic Pte. Ltd.
